isoxazoles has been researched along with Schizophrenia in 414 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (0.72) | 18.7374 |
| 1990's | 104 (25.12) | 18.2507 |
| 2000's | 90 (21.74) | 29.6817 |
| 2010's | 205 (49.52) | 24.3611 |
| 2020's | 12 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Citrome, L; Faden, J | 1 |
| Iwata, N; Kishi, T; Sakuma, K | 1 |
| Hong, H; Liu, L; Mojtabai, R; Stuart, EA | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Narala, A; Suram, D; Veerabrahma, K | 1 |
| Aricioglu, F; Bekci, H; Cumaoglu, A; Unal, G; Yerer, MB | 1 |
| An, JR; Bae, YM; Han, ET; Heo, R; Jung, HS; Kang, M; Park, WS; Seo, MS; Yang, SR | 1 |
| Asamoah, AL; Gosal, R; Grossberg, GT; Nair, A; Salem, A | 1 |
| Aricioglu, F; Sirvanci, S; Unal, G | 1 |
| Kollada, M; Lauritzen, T; Mellem, MS; Tiller, J | 1 |
| Hewitt, T; Khokhar, JY; Lalonde, J; Perreault, ML; St-Denis, M; Thériault, RK | 1 |
| Danek, PJ; Daniel, WA; Kuban, W | 1 |
| Baymeeva, NV; Kaleda, VG; Miroshnichenko, II; Platova, AI | 1 |
| Han, WS; Jung, HY; Kang, UG; Kim, B; Kim, CE; Kim, YS; Lee, JI; Lim, SW; Na, KS; Park, DH; Yoon, JS | 1 |
| Gobburu, JV; Laughren, TP; Mathis, M; Wang, Y; Younis, IR | 1 |
| Alphs, L; Amatniek, J; Canuso, CM; Deutsch, SI; Henderson, DC; Mao, L; Mikesell, C; Rodriguez, S; Sheehan, J | 1 |
| Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Otomo, M; Suzuki, H | 2 |
| Guan, CH; Tsai, SJ | 1 |
| Alphs, L; Bossie, CA; Fu, DJ; Kern Sliwa, J; Ma, YW | 2 |
| Chen, CL; Chou, HW | 1 |
| Amrutheshwar, R; Dkhar, SA; George, M; Kattimani, S; Rajkumar, RP | 1 |
| Kirk Morton, N; Zubek, D | 1 |
| Fan, B; Hu, J; Hu, S; Huang, M; Li, Y; Liao, Z; Peterson, BS; Tang, J; Wei, N; Xu, D; Xu, Y; Yao, M; Yuan, T; Yue, W; Zhou, W | 1 |
| Ghanizadeh, A; Nikseresht, MS; Sahraian, A | 1 |
| Fukui, N; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Sakai, A; Sanjo, K; Takeuchi, K | 1 |
| Hsieh, TH; Liu, CT | 1 |
| Havaki-Kontaxaki, B; Karaiskos, D; Papadimitriou, GN; Pappa, D | 1 |
| Ahn, YM; Chang, SM; Joo, EJ; Kim, EY; Kim, JJ; Kim, YS; Shim, JC | 1 |
| Einarson, TR; Garg, M; Hemels, ME; Skoupá, J; Veselá, S; Zilbershtein, R | 1 |
| Einarson, TR; Hemels, ME; Jensen, R; Piwko, C; Pudas, H; Vicente, C; Zilbershtein, R | 1 |
| Fudala, PJ; Gomeni, R; Heidbreder, C; Nasser, AF | 1 |
| Greiner, W; Heres, S; Mahlich, J; Zeidler, J | 1 |
| Einarson, TR; Hemels, ME | 1 |
| Gen, K; Hibino, H; Inoue, Y; Matsumoto, H; Mikami, A; Mikami, K; Suzuki, H | 1 |
| Inoue, Y; Ishioka, M; Kubo, K; Tsuchimine, S; Yasui-Furukori, N | 1 |
| Bidzan, L; Blanc, M; Don, L; Herceg, M; Heres, S; Lahaye, M; Maciulis, V; Schreiner, A; Siracusano, A | 1 |
| Alphs, L; Bossie, CA; Fu, DJ; Ma, YW; Sliwa, JK | 2 |
| Attard, A; Cornelius, V; Curtis, V; Olofinjana, O; Taylor, D | 1 |
| Gopal, S; Hough, D; Malaspina, D; Nuamah, I; Opler, M; Savitz, AJ; Singh, J | 1 |
| Dargani, NV; Malhotra, AK | 1 |
| Quilo, CG; Rodríguez-Martínez, A | 1 |
| Hsu, CY; Lin, YH; Shen, YC | 1 |
| Bø, CN; Einarson, TR; Hemels, ME; Jensen, R; Piwko, C; Pudas, H; Vicente, C; Zilbershtein, R | 1 |
| Appolinário, JC; Bressan, RA; Campos, JA; de Oliveira, IR; Elkis, H; Gattaz, WF; Grabowski, HM; Henna, E; Lacerda, AL; Lawson, FL; Louzã, MR; Périco, Cde A; Quevedo, J; Rocha, FL; Ruschel, SI; Sacomani, E; Zorzetto Filho, D | 1 |
| Kwak, KH; Lee, SJ; Lim, MS; Seong, SJ; Yang, DS; Yoon, YR | 1 |
| Olofinjana, O; Taylor, D | 1 |
| Koliutskaia, EV; Smulevich, AB | 1 |
| Dai, G; Zhang, Y | 1 |
| Fudala, PJ; Gomeni, R; Heidbreder, C; Laffont, CM; Nasser, AF; Zheng, B | 1 |
| Dilbaz, N; Franco, MA; Lahaye, M; Lara, E; Millet, B; Naber, D; Neznanov, NG; Peuskens, J; Rancans, E; Schreiner, A; Smeraldi, E; Turczynski, J | 1 |
| Cheng, CC; Chou, HW; Hsu, YC; Pan, PY; Tzeng, NS | 1 |
| Chang, CC; Lai, TJ; Wang, WF | 1 |
| Alva, G; Brams, M; Citrome, L; Glick, ID; Hochfeld, M; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Pestreich, L; Weiden, PJ; Winseck, A | 1 |
| Alphs, L; Bossie, CA; Fu, DJ; Sliwa, JK; Turkoz, I | 1 |
| Gopal, S; Liang, S; Liu, Y; Nuamah, I; Rui, Q; Wang, Y; Wu, Q; Wu, Y | 1 |
| Li, H; Liu, Y; Rui, Q; Shu, L; Si, T; Su, Y; Zhang, H | 1 |
| Diels, J; Hargarter, L; Hitschfield, K; Lee, JI; Lenskaya, I; Schreiner, A; Sulaiman, AH | 1 |
| Jayathilake, K; Johnson, R; Kwentus, J; Lindenmayer, JP; Meltzer, HY; Share, DB | 1 |
| Berwaerts, J; Cleton, A; Crauwels, H; De Meulder, M; Eerdekens, M; Gopal, S; Hough, D; Remmerie, B; Rossenu, S; Rosso, CM; Vandebosch, A | 1 |
| Wearne, D | 1 |
| Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C | 1 |
| Li, Y; Liu, X; Sun, F; Teng, L; Wang, D; Zhao, J; Zhou, Y | 1 |
| Buckley, PF; Byerly, M; Dominik, R; Hamer, RM; Lamberti, JS; McEvoy, JP; Ray, N; Rosenheck, RA; Stroup, TS; Swartz, MS; Wilkins, TM | 1 |
| Chang, CL; Chen, YL; Kao, WT; Lung, FW | 1 |
| Alva, G; Citrome, L; Glick, ID; Jackson, R; Kianifard, F; Mattingly, G; Meng, X; Weiden, PJ; Winseck, A | 1 |
| Alphs, L; Hulihan, J; Mao, L; Rodriguez, SC; Starr, HL | 1 |
| Artal, J; Crespo-Facorro, B; Gómez-Ruíz, E; Rodríguez-Rodríguez, P; Vázquez-Bourgon, J | 1 |
| Hamer, J; Kanaan, RA; Norman, TR | 1 |
| Helland, A; Spigset, O; Syrstad, VE | 1 |
| Geerts, H; Potkin, S; Roberts, P; Spiros, A | 1 |
| Duh, MS; Fasteneau, J; Fortier, J; Grittner, AM; Lafeuille, MH; Lefebvre, P; Muser, E | 1 |
| Alphs, L; Chung, H; Cohen, N; Favis, R; Fu, DJ; Gopal, S; Haas, M; Li, Q; Savitz, A; Shapiro, A; Wang, D; Wu, X | 1 |
| Bressan, RA; Hallak, JE; Machado-de-Sousa, JP; Maia-de-Oliveira, JP; Nunes, EA; Ushirohira, JM | 1 |
| Floyd, KL; Stevens, KE; Stitzel, JA; Zheng, L | 1 |
| Berwaerts, J; Coppola, D; Gopal, S; Hough, DW; Liu, Y; Maruta, N; Nuamah, I; Remmerie, B; Savitz, A; Schotte, A; Xu, H | 1 |
| Alphs, L; Benson, C; Cheshire-Kinney, K; Lindenmayer, JP; Mao, L; Rodriguez, SC; Starr, HL | 1 |
| Mandrioli, R; Mercolini, L; Protti, M | 1 |
| Buchanan, RW; Carpenter, WT | 1 |
| Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nishida, K; Onohara, A; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Yoshimura, M | 1 |
| Ahmed, S; Han, G; Mancione, L; Manning, R; Mayo, MG; Ryan, JM; Weiden, PJ; Wolfgang, CD | 1 |
| Bailey, CD; Chung, BY; Cloke, JM; De Lisio, S; Kim, JC; Nguyen, R; Wasserman, DI; Winters, BD | 1 |
| Hołuj, M; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Edmonds, SA; Freedman, R; Gee, KW; Harris, J; Hogenkamp, D; Johnson, L; Johnstone, T; Kanner, R; Olincy, A; Sauer, W; Tran, M; Yoshimura, R | 1 |
| Hamilton, J; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Thompson, A; Volpi, S; Wolfgang, CD | 1 |
| Hamilton, JB; Heaton, C; Lannan, R; Lavedan, C; Licamele, L; Mack, K; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Bossie, CA; Canuso, CM; Schreiner, A; Simpson, GM; Turkoz, I; Youssef, EA | 1 |
| Janicak, PG; Mao, L; Wu, JH | 1 |
| Darby, JK; Herbert, J; Pasta, DJ; Wilson, MG | 1 |
| Aravagiri, M; Bies, RR; Coley, K; Feng, Y; Kirshner, M; Marder, S; Miller, D; Pollock, BG; Schneider, L | 1 |
| Caballero, J; Marino, J | 2 |
| Berwaerts, J; Eerdekens, M; Emsley, R; Hough, D; Kramer, M; Lane, R; Lim, P; Palumbo, J | 1 |
| Chen, CC; Chiu, CC; Huang, MC; Pan, CH; Peng, PW; Tsai, CJ | 1 |
| Jones, A | 1 |
| Adriaenssen, I; Burns, T; Gagnon, DD; Morosini, P; Patrick, DL; Rothman, M; Wild, D | 1 |
| Graff-Guerrero, A; Kapur, S; Mamo, DC; Mulsant, BH; Pollock, BG; Uchida, H | 1 |
| Marchese, G; Pani, L | 1 |
| Chino, B; Kosaki, K; Mizuno, M; Sakuma, K; Sato, Y; Takao, T; Takebayashi, T; Yagihashi, T | 1 |
| Che, R; Du, J; Feng, G; Gu, N; He, L; Li, X; Lin, Z; Wang, L; Xing, Q; Xuan, J; Yu, L; Zhang, A | 1 |
| Bossie, CA; Canuso, CM; Carothers, J; Damaraju, CV; Dirks, B; Kalali, AH; Kosik-Gonzalez, C; Mahmoud, R; Zhu, Y | 1 |
| Cho, HK; Han, C; Jung, BJ; Jung, SM; Kang, RH; Kim, KA; Kim, SH; Kim, YK; Lee, DK; Lee, MS; Park, JY | 1 |
| Chen, CH; Chiu, CC; Huang, MC; Lai, YC; Pan, CH; Tsai, CJ | 1 |
| Furukori, H; Kaneko, S; Kondo, T; Nakagami, T; Saito, M; Suzuki, A; Yasui-Furukori, N | 1 |
| Eerdekens, M; Gopal, S; Herben, V; Hough, D; Lim, P; Lindenmayer, JP; Melkote, R; Yuen, E | 1 |
| Bossie, CA; Canuso, CM; Sheehan, JJ; Turkoz, I | 1 |
| Angelucci, F; Bria, P; Caltagirone, C; Martinotti, G; Ricci, V | 1 |
| Alphs, L; Bossie, CA; Canuso, CM; Turkoz, I | 1 |
| Lavedan, C; Licamele, L; Malhotra, AK; Potkin, SG; Volpi, S | 1 |
| Williams, M | 1 |
| Citrome, L | 8 |
| Samtani, MN; Stuyckens, K; Vermeulen, A | 1 |
| Scott, LJ | 1 |
| Gagnon, DD; Hough, D; Lim, P; Nuamah, IF; Rothman, M; Sampson, A | 1 |
| Berwaerts, J; Boom, S; Cleton, A; Eerdekens, M; Janssens, L; Kramer, M; Remmerie, B; Rossenu, S; Talluri, K | 1 |
| Eerdekens, M; Hough, D; Kramer, M; Lane, R; Lim, P; Litman, R; Liu, Y | 1 |
| Cutler, AJ | 1 |
| Eerdekens, M; Gopal, S; Hough, D; Lim, P; Morozova, M; Vijapurkar, U | 2 |
| Chang, JP; Huang, CC; Su, KP | 1 |
| Alphs, L; Gassmann-Mayer, C; Gopal, S; Palumbo, J; Samtani, MN; Shiwach, R | 1 |
| Lavedan, C; Thompson, A; Volpi, S | 1 |
| Ortega, I; Perez-Ruixo, JJ; Piotrovsky, V; Stuyckens, K; Vermeulen, A | 1 |
| Goulia, P; Hyphantis, T; Kalabokis, G; Mantas, C; Mavreas, V; Tourlakopoulos, A | 1 |
| Kecskés, I | 1 |
| Hoy, SM; Keating, GM; Scott, LJ | 1 |
| Gründer, G; Orfanos, S; Paulzen, M | 1 |
| Amatniek, J; Bossie, CA; Canuso, CM; Cornblatt, B; Pandina, G; Turkoz, I | 1 |
| Adriaenssen, I; Burns, T; Gagnon, DD; Morosini, P; Patrick, DL; Rothman, M | 1 |
| Alphs, L; Awad, AG; Canuso, CM; Damaraju, CV; Grinspan, A; Kalali, A; Merriman, U | 1 |
| Caccia, S; Nobili, A; Pasina, L | 1 |
| Brown, DW; Eerdekens, MH; Gassmann-Mayer, C; Gopal, S; Hough, DW; Lull, JM; Remmerie, BM; Xu, H | 1 |
| Madhusoodanan, S; Zaveri, D | 1 |
| Baldi, ML; Cerveri, G; De Gaspari, IF; Mauri, MC; Mencacci, C; Papa, P; Rolandi, ML; Volonteri, LS | 1 |
| Gopal, S; Herben, V; Kusumakar, V; Lim, P; Lindenmayer, JP; Lull, J; Palumbo, J; Pandina, GJ; Yuen, E | 1 |
| Jones, MP; Nicholl, D; Trakas, K | 1 |
| Hsieh, CH; Liou, YJ | 1 |
| Eerdekens, M; Gassmann-Mayer, C; Gopal, S; Hough, D; Lim, P; Nasrallah, HA; Quiroz, JA; Yuen, E | 1 |
| Božina, N; Jakovljević, M; Jovanović, N; Lovrić, M; Medved, V; Peleš, AM | 1 |
| Chwieduk, CM; Keating, GM | 1 |
| Janicak, PG; Rado, J | 1 |
| Brunetti, L; Patel, MK | 1 |
| Li, Y; Meng, Q; Su, Z; Sui, C; Sun, F; Teng, L; Yuan, L; Zhang, C | 1 |
| Owen, RT | 2 |
| Eerdekens, M; Hough, D; Kramer, M; Kushner, S; Lim, P; Liu, Y; Maciulis, V; Palumbo, J; Simpson, G | 1 |
| English, C; Harrington, CA | 1 |
| D'Souza, DC; Kane, JM; Keefe, RS; Patkar, AA; Tiller, JM; Yang, R; Youakim, JM | 1 |
| Bishop, DL; Bishop, JR | 1 |
| Battisti, WP; Canuso, CM | 1 |
| Eerdekens, M; Hough, DW; Kramer, M; Natarajan, J; Rossenu, S; Vandebosch, A | 1 |
| Damgaard, T; Hansen, SL; Neill, JC; Plath, N | 1 |
| Atallah, AN; Melnik, T; Puga, ME; Soares, BG | 1 |
| Bai, LD; Cao, Y; Gu, DK; Li, WS; Lu, Y; Wang, Y; Yang, N; Zhang, Y | 1 |
| Agarwal, A; Mendhekar, DN | 1 |
| Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Pandina, G; Remmerie, B; Simpson, G | 1 |
| Gill, JS; Jambunathan, S; Koh, OH; Pillai, SK | 1 |
| Canuso, C; Dirani, R; Kozma, C; Mao, L | 1 |
| Han, C; Lee, SJ; Pae, CU | 1 |
| Roman, MW | 1 |
| Dopheide, JA | 2 |
| Arif, SA; Mitchell, MM | 1 |
| Bossie, CA; Canuso, CM; Lindenmayer, JP; Schooler, N; Turkoz, I | 1 |
| Gu, N; Li, H; Ning, X; Rui, Q; Xu, H | 1 |
| Dumontet, J; Ensom, MH; Seto, K | 1 |
| Ahlbrand, R; Bronson, SL; Horn, P; McNamara, RK; Richtand, NM; Stanford, K | 1 |
| Howland, RH | 2 |
| Freudenmann, RW; Gahr, M; Kölle, MA; Lepping, P; Schönfeldt-Lecuona, C | 1 |
| Lin, WK; Lung, FW; Tsai, JK | 1 |
| Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
| Adelsky, M; Adler, DN; Brenner, R; Madhusoodanan, S; Serper, MR | 1 |
| Crabtree, BL; Montgomery, J | 1 |
| Cai, HL; Li, HD; Li, LF; Zhang, J; Zhu, RH | 1 |
| Harada, Y; Koh, T; Nagino, K | 1 |
| Case, M; Hoffmann, VP; Jacobson, JG | 1 |
| Karaiskos, D; Liappas, I; Paparrigopoulos, T; Tzavellas, E | 1 |
| Dirani, R; Fastenau, J; Gopal, S; Hough, D; Kozma, CM; Slaton, T | 1 |
| Ahlbrand, R; Bronson, SL; Gudelsky, G; Kern, JR; Richtand, NM; Roenker, NL; Waterman, H | 1 |
| Citrome, L; Hochfeld, M; Meng, X | 1 |
| Araud, T; Berger, R; Bertrand, D; Graw, S; Lee, M; Leonard, S; Neveu, E | 1 |
| Alphs, L; Bossie, CA; Ma, YW; Sliwa, JK | 1 |
| Eerdekens, M; Fleischhacker, WW; Gassmann-Mayer, C; Gopal, S; Hough, D; Lane, R; Lim, P; Remmerie, B | 1 |
| Conley, RR; Fijal, BA; Hoffmann, VP; Houston, JP; Kinon, BJ; Stauffer, VL; Witte, MM; Zhao, F | 1 |
| Hough, D; Nuamah, I; Robb, A; Singh, J; Vijapurkar, U | 1 |
| Fujii, A; Kaneko, S; Nakagami, T; Saito, M; Sugawara, N; Tsuchimine, S; Yasui-Furukori, N | 1 |
| Alphs, L; Gassmann-Mayer, C; Gopal, S; Palumbo, JM; Samtani, MN | 1 |
| Lai, CH | 2 |
| Liang, CS; Yang, FW | 1 |
| Gilday, E; Nasrallah, HA | 1 |
| Citrome, L; Hochfeld, M; Meng, X; Stahl, SM | 1 |
| DiCrescento, S; Perry, R; Wolberg, J | 1 |
| Mori, T | 1 |
| Chan, CH; Cheng, KS; Chiu, WC; Huang, MW; Lan, TH; Li, CY; Liu, IC; Su, PW; Ten, PR; Wu, BJ; Yang, TT; Yeh, YC | 1 |
| Fountoulakis, KN; Panagiotidis, P | 1 |
| Duncan, GE; Koller, BH; Moy, SS | 1 |
| Singh, D; Williams, O | 1 |
| Hustig, H; Lakshmana, R; Lee, J; Motamarri, B; Newton, R; Norrie, P; Parker, R; Schreiner, A | 1 |
| Guerdjikova, AI; Keck, PE; Martens, B; McCoy, J; McElroy, SL; Moeller, D; Mori, N; Winstanley, E | 1 |
| Bies, RR; Mamo, DC; Mimura, M; Pollock, BG; Suzuki, T; Tsunoda, K; Uchida, H; Watanabe, K | 1 |
| Coffey, MJ | 1 |
| Emsley, R; Gopal, S; Hough, D; Nuamah, I | 1 |
| Weiden, PJ | 1 |
| Coppola, D; Gopal, S; Hough, DW; Liu, Y; Nuamah, I; Pandina, G; Remmerie, B; Samtani, MN; Sulaiman, A | 1 |
| Martin, M; McGuire, A; Mehnert, A; Nicholl, D; Pudas, H | 1 |
| Ahn, YM; Chee, IS; Chung, YC; Go, HJ; Jae, YM; Joe, S; Jung, SW; Kim, CE; Kim, SW; Kim, YD; Kim, YS; Kwon, YJ; Lee, J; Yoon, BH; Yoon, JS | 1 |
| Chung, TS; Lung, FW | 1 |
| Carter, NJ | 1 |
| Nussbaum, AM; Stroup, TS | 3 |
| Morozova, MA | 1 |
| Aadamsoo, K; Bergmans, P; Fernández, LG; Hoeben, D; Korcsog, P; Niehaus, D; Salinas, R; Schreiner, A; Shuriquie, NA; Tessier, C; Theodoropoulou, P; Uçok, A | 1 |
| Fukui, N; Inoue, Y; Ono, S; Saito, M; Someya, T; Sugai, T; Suzuki, Y; Tsuneyama, N; Watanabe, J | 1 |
| Badescu, GM; Bidzan, L; Hoeben, D; Jukić, V; Lahaye, M; Maciulis, V; Schmauss, M; Schreiner, A; Siracusano, A; Tessier, C | 1 |
| Hopkins, CR | 1 |
| Ahn, YM; Jung, HY; Kim, CE; Kim, WH; Kim, YS; Min, KJ; Na, KS; Park, KC; Ryu, SG; Yoon, JS | 1 |
| Bae, KY; Chung, YC; Kim, JM; Kim, SW; Kim, SY; Lee, JH; Lee, YH; Shin, IS; Yoon, JS | 1 |
| Brandon, NJ; Engle, SJ; Jaaro-Peled, H; Rais, R; Rojas, C; Sawa, A; Slusher, BS; Strick, CA; Thomas, AG; Tsukamoto, T; Wozniak, K; Wu, Y | 1 |
| Stahl, SM; Tarazi, FI | 1 |
| Correll, CU; De Hert, M; Detraux, J; Sweers, K; van Winkel, R; Yu, W | 1 |
| Den, R; Hirano, J; Ikai, S; Mamo, D; Mimura, M; Nishimoto, M; Remington, G; Suzuki, T; Takeuchi, H; Tsuboi, T; Tsunoda, K; Uchida, H; Watanabe, K | 1 |
| Banaag, C; Bautista, J; Choi, A; Dimatalac, B; Evangelista, ML; Kongsakon, R; Lim, L; Lo, WT; Nerapusee, O; Singh, S; Sobrevega, E; Thavichachart, N | 1 |
| Baca, E; Bobes, J; Cañas, F; Gonzalez, B; Heeg, B; Salvador, L; Treur, M | 1 |
| Kandasamy, A | 1 |
| Aksoy-Poyraz, C; Kılıç-Yener, E; Özdemir, A | 1 |
| Perry, CM | 1 |
| Baandrup, L; Glenthoj, B; Jennum, P; Lublin, H | 1 |
| Chue, J; Chue, P | 1 |
| Baker, GB; Chue, JA; Chue, PS; MacKenzie, EM | 1 |
| Andrade, C; Suresh Kumar, PN | 1 |
| Bobo, WV | 1 |
| Lai, TJ; Teng, PR | 1 |
| Cutler, AJ; Kalali, AH; Kunovac, J; Mattingly, GW; Meng, X | 1 |
| Carano, A; Cavuto, M; De Berardis, D; Di Giannantonio, M; Fornaro, M; Iasevoli, F; Lang, AP; Marini, S; Martinotti, G; Mazza, M; Perna, G; Piersanti, M; Valchera, A | 1 |
| Freeman, SA | 1 |
| Berecz, R; de la Rubia, A; Degrell, I; Dorado, P; Gómez, J; Kellermann, M; LLerena, A | 1 |
| De Vries, R; Iga, T; Kaneko, S; Kondo, T; Kubota, T; Mihara, K; Takarada, Y; Tateishi, T; Yasui-Furukori, N | 1 |
| de Vries, R; Iga, T; Ishida, M; Kaneko, S; Kondo, T; Kubota, T; Mihara, K; Ono, S; Suzuki, A; Takarada, Y; Yasui-Furukori, N | 1 |
| Chang, JW; Chen, PS; Liao, YC; Su, SF; Yang, YK; Yeh, TL | 1 |
| De Vries, R; Kaneko, S; Kondo, T; Mihara, K; Nakagami, T; Suzuki, A; Takahata, T; Tateishi, T; Yasui-Furukori, N | 1 |
| Ancione, M; D'Arrigo, C; Madia, A; Migliardi, G; Morgante, L; Spina, E; Zoccali, R | 1 |
| Möller, HJ; Müller, N; Müller-Arends, A; Riedel, M; Schwarz, MJ; Spellmann, I; Strassnig, M; Weber, K; Zach, J | 1 |
| Castberg, I; Spigset, O | 1 |
| Björner, A; Eerdekens, M; Eriksson, B; Gefvert, O; Helldin, L; Mannaert, E; Nyberg, S; Persson, P; Remmerie, B | 1 |
| Goto, M; Kaji, K; Kakihara, S; Matsumoto, C; Nakamura, J; Ohmori, O; Shinkai, K; Ueda, N; Yamada, Y; Yoshimura, R | 1 |
| Cha, MY; Cho, H; Choi, KI; Jeong, D; Koh, HY; Kong, JY; Lee, SJ; Pae, AN; Park, WK | 1 |
| Furukori, H; Kaneko, S; Nakagami, T; Saito, M; Yasui-Furukori, N | 1 |
| Byun, WT; Cho, HK; Jung, IG; Jung, SM; Kim, KA; Park, JY; Park, PW | 1 |
| Deng, CY; Li, HD; Li, WB; Li, X; Lin, QX; Lin, SG; Peng, HY; Su, FL; Wang, CY; Wang, F; Yang, M; Yu, XY; Zhou, ZL; Zhu, RH | 1 |
| Kapur, S; Labelle, A; Mamo, D; Mann, S; Mannaert, E; Reiss, J; Remington, G; Shammi, C | 1 |
| Hendset, M; Nesvåg, R; Refsum, H; Tanum, L | 1 |
| Oberpichler-Schwenk, H | 1 |
| Duan, S; Feng, G; Gao, R; He, L; Li, H; Meng, J; Qin, S; Xing, Q; Xu, M; Zhang, A | 1 |
| Canas, F; Eerdekens, M; Ford, L; Gassmann-Mayer, C; Kane, J; Kramer, M; Lim, P | 1 |
| Melkersson, KI | 1 |
| Eerdekens, M; Kramer, M; Kushner, S; Lim, P; Maciulis, V; Simpson, G; Vijapurkar, U | 1 |
| Nakamura, J; Shinkai, K; Ueda, N; Yoshimura, R | 1 |
| Plosker, GL; Yang, LP | 1 |
| Hori, H; Kakihara, S; Mitoma, M; Nakamura, J; Nakano, Y; Ohta, M; Shinkai, K; Shinkai, T; Sugita, A; Ueda, N; Umene, W; Yoshimura, R | 1 |
| Davidson, M; Eerdekens, M; Emsley, R; Ford, L; Kramer, M; Lim, P; Pan, G | 1 |
| D'Hoore, P; Kushner, S; Mannaert, E; Remmerie, B; Thyssen, A | 1 |
| Canuso, CM; Kujawa, M; Mahmoud, R; Pandina, GJ; Youssef, E | 1 |
| Eerdekens, E; Eerdekens, M; Ford, L; Kramer, M; Lim, P; Lowy, A; Marder, SR | 1 |
| Battisti, WP; Cleton, A; Eerdekens, M; Gassmann-Mayer, C; Luthringer, R; Muzet, M; Noel, N; Palumbo, JM; Staner, L; Talluri, K | 1 |
| Du, J; Fang, C; Feng, GY; Gu, NF; He, L; Li, XW; Qin, SY; Wang, L; Xing, QH; Yu, L; Zhang, AP | 1 |
| Dlugosz, H; Nasrallah, HA | 1 |
| Cavallaro, R; Spina, E | 1 |
| Arakawa, R; Ito, H; Kato, M; Morimoto, T; Ohta, K; Okubo, Y; Sassa, T; Suhara, T; Takahashi, H; Takano, A | 1 |
| Albers, LJ; Musenga, A; Raggi, MA | 1 |
| Eerdekens, M; Ford, L; Gassmann-Mayer, C; Kramer, M; Lim, P; Samokhvalov, V; Tzimos, A | 1 |
| Heinz, A; Lautenschlager, M | 1 |
| Deyo, Z; Dolder, C; Nelson, M | 1 |
| Lavedan, C; Polymeropoulos, MH; Volpi, S; Wolfgang, CD | 1 |
| Potkin, SG | 1 |
| Cutler, AJ; Polymeropoulos, MH; Weiden, PJ; Wolfgang, CD | 1 |
| Cutler, AJ; Hamilton, J; Kalali, AH; Weiden, PJ; Wolfgang, CD | 1 |
| Di Marino, M; Kane, JM; Laska, E; Lauriello, J; Wolfgang, CD | 1 |
| Litman, RE; Potkin, SG; Torres, R; Wolfgang, CD | 1 |
| Argo, TR; Bettinger, TL; Fowler, JA | 1 |
| Nussbaum, A; Stroup, TS | 1 |
| Bobo, WV; Eerdekens, M; Hough, D; Kramer, M; Lane, R; Meltzer, HY; Nuamah, IF | 1 |
| Altmann, H; Dose, M; Emrich, HM; von Zerssen, D | 1 |
| Kerwin, R | 1 |
| Jeffries, JJ | 1 |
| MacEwan, GW | 1 |
| Ereshefsky, L; Lacombe, S | 1 |
| Arnott, W; Chouinard, G | 1 |
| Remington, GJ | 2 |
| Kane, JM | 4 |
| Busatto, GF; Costa, DC; Ell, PJ; Kerwin, RW; Pilowsky, LS; Verhoeff, NP | 2 |
| Livingston, MG | 1 |
| Fensbo, C; Høyberg, OJ; Lingjaerde, O; Remvig, J; Salvesen, I; Sloth-Nielsen, M | 1 |
| Kerwin, RW | 1 |
| Marder, SR; Meibach, RC | 1 |
| Awouters, FH; Janssen, PA | 1 |
| Davidson, JE; Mosqueda, RA | 1 |
| Edwards, JG | 1 |
| Lindström, E; von Knorring, L | 4 |
| Dalby, JT; Dickson, R; Williams, R | 1 |
| Land, W; Salzman, C | 1 |
| Littrell, K; Schultz, RE | 1 |
| Jahnová, E | 1 |
| Mok, H; Yatham, LN | 1 |
| Heykants, J; Huang, ML; Mannens, G; Meuldermans, W; Snoeck, E; Van Beijsterveldt, L; Van Peer, A; Woestenborghs, R | 1 |
| Schooler, NR | 1 |
| McEvoy, JP | 1 |
| Owens, DG | 1 |
| Honer, WG; Kopala, L | 1 |
| Goldberg, TE; Weinberger, DR | 1 |
| Cozza, SJ; Edison, DL | 1 |
| Finlayson, R; Jones, BD; Labelle, A; Purdon, SE | 1 |
| Fitton, A; Grant, S | 1 |
| Eilers, R | 1 |
| Bennett, JA; Keck, PE; Wallhausser, LJ | 1 |
| Bennie, EH | 1 |
| Borison, RL; Diamond, B; Meibach, RC; Pathiraja, A | 1 |
| Beaudry, P; Bélanger, MC; Chouinard, G; Miller, R; Roy, JY; Turnier, L; Vainer, JL | 1 |
| Furukawa, H; Hasegawa, T; Kitaichi, K; Nabeshima, T; Yamada, K | 1 |
| Keegan, D | 1 |
| Villeneuve, A | 1 |
| Sigmundson, HK | 1 |
| Lee, MA; Meltzer, HY; Ranjan, R | 1 |
| Black, DW; Gupta, S; Smith, DA | 1 |
| Honer, WG; Kopala, LC | 1 |
| Clarke, DE; Yaeger, SF | 1 |
| Bryois, C | 1 |
| Ericsson, B; Farde, L; Halldin, C; Nakashima, Y; Nyberg, S; Oxenstierna, G | 1 |
| Borison, RL | 1 |
| Chouinard, G | 1 |
| Heinrich, K; Kinzler, E; Klieser, E; Lehmann, E; Wurthmann, C | 1 |
| Love, RC | 1 |
| Perry, PJ | 1 |
| Curtis, VA; Kerwin, RW | 1 |
| Breier, A | 1 |
| Sternlicht, HC; Wells, SR | 1 |
| Pickar, D | 1 |
| Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR | 1 |
| McEvoy, JP; Price, WA; Swanson, CL | 1 |
| Byerly, MJ; Evans, DL; Greer, RA | 1 |
| Zimbroff, DL | 1 |
| Dalby, JT; Dickson, RA; Edwards, AL; Williams, R | 1 |
| Pelonero, AL | 1 |
| Price, PL | 1 |
| Möller, HJ | 1 |
| Lindenmayer, JP | 1 |
| Azorin, JM | 1 |
| Aubert, AC; Baumann, P; Bondolfi, G; Meylan, C | 1 |
| Huttunen, MO; Larmo, I; Nyholm, R; Piepponen, T; Raitasuo, V; Rantanen, H | 1 |
| Allen, M; Field, K; Ganguli, R; Reddy, R; Tanner, TB | 1 |
| Cott, J; Lieberman, JA; Matthews, S; Shore, D | 1 |
| Borison, RL; Brown, TM; Radford, JM | 1 |
| Kirisci, L; Musser, WS | 1 |
| Goss, JB | 1 |
| Houle, S; Kapur, S; Remington, G; Wilson, AA; Zipursky, RB | 1 |
| Jerkovich, GS; Lacey, RL; Preskorn, SH | 1 |
| Cardoni, AA | 1 |
| Peuskens, J | 1 |
| Kane, JM; McGlashan, TH | 1 |
| Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G | 1 |
| Menkes, DB | 1 |
| Aravagiri, M; Marder, SR; Midha, KK; Van Putten, T | 1 |
| Kang, DY; Kim, CE; Min, SK; Rhee, CS | 1 |
| Czobor, P; Volavka, J | 1 |
| Cesková, E; Svestka, J | 1 |
| Aravagiri, M; Marder, SR; Wirshing, D; Wirshing, WC | 1 |
| Avenoso, A; Dahl, ML; Facciolà, G; Johansson, I; Scordo, MG; Spina, E | 1 |
| Furukori, H; Kaneko, S; Nagasaki, T; Ohkubo, T; Sugawara, K; Yasui, N | 1 |
| Chang, WH; Chiu, WC; Chou, JC; Lane, HY; Su, MH; Wu, ST | 1 |
| Aravagiri, M; Marder, SR | 1 |
| Nakamura, J; Terao, T; Ueda, N; Yoshimura, R | 1 |
| Jain, KK | 1 |
| Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E | 1 |
| Nakamura, J; Ueda, N; Yoshimura, R | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Bollen, J; Claus, A; De Cuyper, H; Eneman, M; Heylen, S; Malfroid, M; Peuskens, J | 1 |
| Baert, AL; Bollen, J; Claus, A; De Cuyper, H; Eneman, M; Heylen, S; Malfroid, M; Peuskens, J; Van Ongeval, C; Wilms, G | 1 |
| Gelders, YG; Heylen, SL | 1 |
| Müller-Spahn, F | 1 |
| Marder, SR | 1 |
| Borison, RL; Diamond, BI; Meibach, RC; Pathiraja, AP | 1 |
| Gerlach, J | 1 |
| Kissling, W; Möller, HJ; Pelzer, E; Riehl, T; Wernicke, T | 1 |
| Gelders, YG | 1 |
| Alphs, LD; Ferraro, TN; Hare, TA; Lafferman, J; Tamminga, CA; Thaker, GK | 1 |
105 review(s) available for isoxazoles and Schizophrenia
| Article | Year |
|---|---|
Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Network Meta-Analysis; Paliperidone Palmitate; Prolactin; Pyrimidines; Schizophrenia; Treatment Outcome | 2022 |
Calibrated meta-analysis to estimate the efficacy of mental health treatments in target populations: an application to paliperidone trials for treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Mental Health; Paliperidone Palmitate; Randomized Controlled Trials as Topic; Schizophrenia | 2023 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
An update on the efficacy and safety of iloperidone as a schizophrenia therapy.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Weight Gain | 2020 |
Newer antipsychotics and upcoming molecules for schizophrenia.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2013 |
[Paliperidone, risperidone].
Topics: Antipsychotic Agents; Humans; Isoxazoles; Japan; Paliperidone Palmitate; Pyrimidines; Receptor, Serotonin, 5-HT2A; Risperidone; Schizophrenia; Treatment Outcome | 2013 |
Safety profile of iloperidone in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2014 |
Paliperidone extended-release: safety and tolerability from a metabolic profile perspective.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Glucose; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Weight Gain | 2013 |
Novel Atypical Antipsychotics: Metabolism and Therapeutic Drug Monitoring (TDM).
Topics: Animals; Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Drug Design; Drug Monitoring; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
Paliperidone extended-release for the treatment of schizophrenia.
Topics: Acute Disease; Antipsychotic Agents; Delayed-Action Preparations; Drug Interactions; Fees, Pharmaceutical; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2008 |
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Multicenter Studies as Topic; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Tablets; Time Factors; Treatment Outcome | 2008 |
Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome | 2009 |
Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Drug Labeling; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Sample Size; Schizophrenia; Treatment Outcome | 2009 |
Iloperidone: in schizophrenia.
Topics: Humans; Internationality; Isoxazoles; Multicenter Studies as Topic; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology | 2009 |
Paliperidone palmitate - review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication.
Topics: Administration, Oral; Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Randomized Controlled Trials as Topic; Schizophrenia; Tablets; Treatment Outcome | 2010 |
Iloperidone: a new option for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Brief Psychiatric Rating Scale; Clinical Trials as Topic; Confidence Intervals; Humans; Isoxazoles; Kaplan-Meier Estimate; Longitudinal Studies; Piperidines; Schizophrenia | 2009 |
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Drug Administration Schedule; Drug Dosage Calculations; Health Planning Guidelines; Humans; Isoxazoles; Maximum Tolerated Dose; Models, Biological; Paliperidone Palmitate; Palmitates; Pyrimidines; Schizophrenia; Withholding Treatment | 2010 |
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Isoxazoles; Models, Psychological; Olanzapine; Paliperidone Palmitate; Principal Component Analysis; Psychometrics; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Time Factors | 2010 |
Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Multicenter Studies as Topic; Paliperidone Palmitate; Placebo Effect; Psychiatric Status Rating Scales; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Social Behavior; Tablets; Time Factors; Treatment Outcome | 2010 |
New atypical antipsychotics for schizophrenia: iloperidone.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2010 |
Paliperidone use in the elderly.
Topics: Age Factors; Aged; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Humans; Isoxazoles; Nervous System Diseases; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2010 |
Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Regression Analysis; Schizophrenia | 2010 |
Paliperidone extended release: a review of its use in the management of schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2010 |
Iloperidone for schizophrenia.
Topics: Animals; Antipsychotic Agents; Dopamine Antagonists; Drug Approval; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2010 |
Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia.
Topics: Antipsychotic Agents; Dosage Forms; Drug Storage; Evidence-Based Medicine; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia | 2010 |
Iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Drug Interactions; Evidence-Based Medicine; Humans; Isoxazoles; Pharmacogenetics; Piperidines; Precision Medicine; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.
Topics: Animals; Bipolar Disorder; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
Topics: Adult; Animals; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Half-Life; Humans; Isoxazoles; Piperidines; Receptors, Adrenergic, alpha-1; Schizophrenia | 2010 |
Change in employment status over 52 weeks in patients with schizophrenia: an observational study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Employment; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Observation; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Time Factors | 2011 |
Iloperidone: A new drug for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Interactions; Humans; Isoxazoles; Piperidines; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic; Schizophrenia | 2011 |
Risperidone in schizophrenia: is there a role for therapeutic drug monitoring?
Topics: Antipsychotic Agents; Drug Monitoring; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2011 |
Paliperidone extended-release: does it have a place in antipsychotic therapy?
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2011 |
Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2011 |
Iloperidone for the management of adults with schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia; Treatment Outcome | 2011 |
[Pharmacological properties of paliperidone ER (INVEGA(®)) and results of its clinical studies].
Topics: Animals; Behavior, Animal; Catalepsy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Double-Blind Method; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention | 2011 |
Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Injections, Intramuscular; Isoxazoles; Models, Biological; Paliperidone Palmitate; Palmitates; Schizophrenia | 2011 |
Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia | 2012 |
Iloperidone: a clinical overview.
Topics: Antipsychotic Agents; Electrocardiography; Heart Rate; Humans; Isoxazoles; Long QT Syndrome; Piperidines; Schizophrenia; Treatment Outcome; Weight Gain | 2011 |
Practical guidelines on the use of paliperidone palmitate in schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Patient Compliance; Practice Guidelines as Topic; Pyrimidines; Schizophrenia | 2012 |
Iloperidone for the treatment of schizophrenia: an updated clinical review.
Topics: Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Hospitalization; Humans; Isoxazoles; Piperidines; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2012 |
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.
Topics: Administration, Oral; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Half-Life; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2012 |
Paliperidone palmitate for schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2012 |
[Possibilities of the treatment of exacerbations of schizophrenia with the long acting atypical antipsychotic paliperidone palmitate].
Topics: Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia | 2012 |
ACS chemical neuroscience molecule spotlight on Fanapt.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Device Approval; Dopamine Agonists; Humans; Isoxazoles; Piperidines; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT2 Receptor Antagonists; United States; United States Food and Drug Administration | 2010 |
Iloperidone, asenapine and lurasidone: a primer on their current status.
Topics: Adult; Animals; Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
Topics: Antipsychotic Agents; Bipolar Disorder; Blood Glucose; Dibenzocycloheptenes; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lipid Metabolism; Lurasidone Hydrochloride; Paliperidone Palmitate; Piperidines; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Thiazoles; Weight Gain | 2012 |
Second-generation long-acting injectable antipsychotic agents: an overview.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Costs; Humans; Injections; Isoxazoles; Monitoring, Physiologic; Olanzapine; Paliperidone Palmitate; Practice Guidelines as Topic; Pyrimidines; Risperidone; Schizophrenia | 2012 |
Paliperidone palmitate for schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2012 |
Paliperidone extended release: in adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2012 |
Treatment options for residual insomnia in schizophrenia.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Sleep Initiation and Maintenance Disorders | 2013 |
A review of paliperidone palmitate.
Topics: Animals; Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia | 2012 |
The pharmacology and formulation of paliperidone extended release.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2012 |
Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
Topics: Antipsychotic Agents; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Piperidines; Schizophrenia; Thiazoles | 2013 |
Efficacy and safety of long acting injectable atypical antipsychotics: a review.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Drug Delivery Systems; Humans; Injections; Isoxazoles; Medication Adherence; Olanzapine; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia | 2013 |
Paliperidone: quo vadis?
Topics: Adolescent; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Humans; Isoxazoles; Paliperidone Palmitate; Prolactin; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Treatment Outcome | 2007 |
Paliperidone extended release.
Topics: Antipsychotic Agents; Biotransformation; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Tissue Distribution | 2007 |
Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2007 |
Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Patient Compliance; Patient Satisfaction; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Solubility; Tablets; Taste; Therapeutic Equivalency | 2007 |
Paliperidone extended-release tablets: a new atypical antipsychotic.
Topics: Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Monitoring; Humans; Isoxazoles; Long-Term Care; Nurse's Role; Paliperidone Palmitate; Patient Education as Topic; Patient Selection; Psychiatric Nursing; Pyrimidines; Safety; Schizophrenia; Treatment Outcome | 2007 |
Paliperidone: a new extended-release oral atypical antipsychotic.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drugs, Investigational; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Schizophrenic Psychology | 2007 |
The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.
Topics: Animals; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Treatment Outcome | 2007 |
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Humans; Isoxazoles; Marketing; Piperidines; Receptors, Adrenergic; Receptors, Dopamine; Receptors, Serotonin; Schizophrenia; Structure-Activity Relationship | 2008 |
Paliperidone-ER: first atypical antipsychotic with oral extended release formulation.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2008 |
Paliperidone for schizophrenia.
Topics: Antipsychotic Agents; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Drug Interactions; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2008 |
Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Patient Dropouts; Piperidines; Prospective Studies; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia; Weight Gain | 2008 |
Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Prospective Studies; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Humans; Isoxazoles; Metabolic Diseases; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Secondary Prevention; Serotonin Antagonists; Tablets; Treatment Outcome | 2008 |
Paliperidone for treatment of schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2008 |
Paliperidone for schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia | 2008 |
Ethical issues in drug selection for schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Dyskinesia, Drug-Induced; Ethics, Medical; Humans; Informed Consent; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
New antipsychotic medications: do research results relate to clinical practice?
Topics: Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Dyskinesia, Drug-Induced; Humans; Isoxazoles; Neurologic Examination; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1993 |
Pharmacological profile of risperidone.
Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Metabolic Clearance Rate; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Clinical review of risperidone.
Topics: Antipsychotic Agents; Clinical Trials, Phase III as Topic; Humans; Isoxazoles; Multicenter Studies as Topic; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Clinical considerations in the use of risperidone.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential.
Topics: Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Remoxipride; Risperidone; Schizophrenia; Treatment Outcome | 1993 |
Risperidone.
Topics: Antipsychotic Agents; Drug Interactions; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.
Topics: Antipsychotic Agents; Brain; Clozapine; Dyskinesia, Drug-Induced; Extrapyramidal Tracts; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine; Receptors, Serotonin; Remoxipride; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Risperidone: clinical issues in treatment.
Topics: Antipsychotic Agents; Drug Approval; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1994 |
Extrapyramidal side effects and tolerability of risperidone: a review.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Dystonia; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
The effects of clozapine on neurocognition: an overview.
Topics: Clozapine; Cognition; Cognition Disorders; Dopamine; Humans; Isoxazoles; Neuropsychological Tests; Piperidines; Receptors, Dopamine; Receptors, Muscarinic; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1994 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over Studies; Disease Models, Animal; Drug Interactions; Hemodynamics; Humans; Isoxazoles; Neurosecretory Systems; Piperidines; Risperidone; Schizophrenia; Synaptic Transmission; Tissue Distribution | 1994 |
Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug.
Topics: Antipsychotic Agents; Brain; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Pathophysiology and treatment of negative symptoms.
Topics: Antipsychotic Agents; Brain; Depression; Dose-Response Relationship, Drug; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Pharmacotherapy of schizophrenia: a review.
Topics: Antipsychotic Agents; Brain; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Recent advances in the pharmacotherapy of schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain; Clozapine; Dopamine; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone: review of its pharmacology and therapeutic use in schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Placebos; Risperidone; Schizophrenia; Treatment Outcome | 1994 |
[New psychopharmacologic alternatives in treatment of schizophrenia].
Topics: Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Isoxazoles; Piperidines; Psychotropic Drugs; Remoxipride; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.
Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dopamine Antagonists; Humans; Imidazoles; Indoles; Isoxazoles; Olanzapine; Piperidines; Pirenzepine; Risperidone; Schizophrenia; Serotonin Antagonists | 1995 |
Clinical use of the newer antipsychotic drugs.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Clozapine; Female; Formularies as Topic; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1995 |
A risk-benefit assessment of risperidone in schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risk; Risperidone; Schizophrenia | 1995 |
Serotonin, schizophrenia and antipsychotic drug action.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperazines; Piperidines; Risperidone; Schizophrenia; Serotonin; Tryptophan | 1995 |
Prospects for pharmacotherapy of schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
New pharmacotherapeutic modalities for negative symptoms in psychosis.
Topics: Affective Symptoms; Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology; Syndrome | 1995 |
Long-term treatment of mood disorders in schizophrenia.
Topics: Affective Symptoms; Antidepressive Agents; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Isoxazoles; Lithium; Long-Term Care; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Principal components and further possibilities with the PANSS.
Topics: Affective Symptoms; Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Risperidone; Schizophrenia; Schizophrenic Psychology; Syndrome | 1995 |
Antipsychotic medication in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Risperidone: review and assessment of its role in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
Treatment of schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Clozapine; Cognitive Behavioral Therapy; Family Therapy; Humans; Isoxazoles; Piperidines; Psychotherapy; Rehabilitation, Vocational; Risperidone; Schizophrenia | 1995 |
An assessment of iloperidone for the treatment of schizophrenia.
Topics: Animals; Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Schizophrenia | 2000 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Glutamate; Receptors, Neurotransmitter; Receptors, Serotonin; Remoxipride; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride | 1991 |
134 trial(s) available for isoxazoles and Schizophrenia
| Article | Year |
|---|---|
Effectiveness of paliperidone extended-release for patients with schizophrenia: focus on subjective improvement.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2013 |
An integrated approach for establishing dosing recommendations: paliperidone for the treatment of adolescent schizophrenia.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Child; Computer Simulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Follow-Up Studies; Humans; Isoxazoles; Models, Biological; Paliperidone Palmitate; Pyrimidines; Schizophrenia; United States; United States Food and Drug Administration | 2013 |
Study of the efficacy and safety of switching from risperidone to paliperidone in elderly patients with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Patient Satisfaction; Pyrimidines; Risperidone; Schizophrenia | 2013 |
Paliperidone palmitate versus risperidone long-acting injection in markedly-to-severely ill schizophrenia subjects: onset of efficacy with recommended initiation regimens.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2014 |
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Insulin Resistance; Insulin-Secreting Cells; Isoxazoles; Lipid Metabolism; Male; Olanzapine; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Schizophrenia; Time Factors; Young Adult | 2013 |
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Obesity; Schizophrenia; Statistics, Nonparametric; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult; Zonisamide | 2013 |
Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Risperidone; Schizophrenia; Severity of Illness Index | 2013 |
A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Delayed-Action Preparations; Female; Humans; Injections, Subcutaneous; Isoxazoles; Male; Middle Aged; Models, Biological; Paliperidone Palmitate; Polyglactin 910; Prolactin; Pyrimidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Young Adult | 2013 |
The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
Topics: Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Cognition Disorders; Drug Substitution; Dyskinesia, Drug-Induced; Female; Humans; Isoxazoles; Male; Memory, Short-Term; Neuropsychological Tests; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2014 |
Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Predictive Value of Tests; Prospective Studies; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Topics: Adult; Age of Onset; Antipsychotic Agents; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Isoxazoles; Male; Muscle Rigidity; Paliperidone Palmitate; Palmitates; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome | 2014 |
Effect of parental age on treatment response in adolescents with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Double-Blind Method; Female; Humans; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Paliperidone Palmitate; Paternal Age; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Young Adult | 2013 |
Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study.
Topics: Administration, Oral; Adult; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Patient Satisfaction; Prospective Studies; Pyrimidines; Quality of Life; Risperidone; Schizophrenia; Severity of Illness Index | 2014 |
Changes in plasma concentrations of risperidone and 9-hydroxyrisperidone and the associated clinical effects during the switch from oral risperidone to extended-release paliperidone tablets in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Time Factors; Young Adult | 2014 |
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Population pharmacokinetics and prediction of dopamine D2 receptor occupancy after multiple doses of RBP-7000, a new sustained-release formulation of risperidone, in schizophrenia patients on stable oral risperidone treatment.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Injections, Subcutaneous; Isoxazoles; Male; Middle Aged; Models, Biological; Paliperidone Palmitate; Pyrimidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Young Adult | 2014 |
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aortic Bodies; Aripiprazole; Benzodiazepines; Cohort Studies; Drug Administration Schedule; Drug Substitution; Female; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Quinolones; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2014 |
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Female; Humans; Isoxazoles; Lipids; Male; Middle Aged; Obesity; Paliperidone Palmitate; Palmitates; Schizophrenia; Weight Gain; Young Adult | 2014 |
Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophrenia.
Topics: Adolescent; Adult; Age Factors; Aged; Analysis of Variance; Antipsychotic Agents; Asian People; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Humans; Isoxazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paliperidone Palmitate; Proportional Hazards Models; Pyrimidines; Recurrence; Schizophrenia; Young Adult | 2014 |
Pharmacokinetics and tolerability of paliperidone palmitate injection in Chinese subjects.
Topics: Antipsychotic Agents; Asian People; Chromatography, High Pressure Liquid; Constipation; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Isoxazoles; Linear Models; Male; Middle Aged; Pain; Paliperidone Palmitate; Palmitates; Prolactin; Schizophrenia; Tandem Mass Spectrometry; Time Factors; Treatment Outcome; Tremor | 2014 |
A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2014 |
A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Buttocks; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Muscle, Skeletal; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Shoulder | 2014 |
Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.
Topics: Antipsychotic Agents; Double-Blind Method; Humans; Injections; Isoxazoles; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia | 2014 |
Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Treatment Failure; Treatment Outcome; Weight Gain | 2014 |
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dizziness; Female; Humans; Isoxazoles; Male; Olanzapine; Piperazines; Piperidines; Quinolones; Risperidone; Schizophrenia; Treatment Outcome | 2015 |
Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Drug Administration Schedule; Female; Hospitalization; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Time Factors; Treatment Failure; Young Adult | 2014 |
Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Secondary Prevention; Treatment Outcome; Young Adult | 2015 |
Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study.
Topics: Adult; Antipsychotic Agents; Criminals; Female; Hospitalization; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Single-Blind Method; Treatment Failure; Treatment Outcome | 2015 |
Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial.
Topics: Adult; Antipsychotic Agents; Cognition; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome | 2016 |
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Recurrence; Schizophrenia; Secondary Prevention; Treatment Outcome | 2016 |
First in human trial of a type I positive allosteric modulator of alpha7-nicotinic acetylcholine receptors: Pharmacokinetics, safety, and evidence for neurocognitive effect of AVL-3288.
Topics: Adult; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Anilides; Biomarkers; Cognition; Double-Blind Method; Female; Humans; Isoxazoles; Male; Neurocognitive Disorders; Nicotine; Nicotinic Agonists; Receptors, Nicotinic; Schizophrenia; Synaptic Transmission; Young Adult | 2017 |
Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basic Helix-Loop-Helix Transcription Factors; Double-Blind Method; Female; Genome-Wide Association Study; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Isoxazoles; Male; Middle Aged; Nerve Tissue Proteins; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Pseudogenes; Receptors, AMPA; Schizophrenia; Tenascin; Thiazoles; Transcription Factors; Young Adult | 2009 |
Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Carrier Proteins; CELF Proteins; Cytoskeletal Proteins; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Gene Frequency; Genome-Wide Association Study; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Isoxazoles; Linear Models; Linkage Disequilibrium; Long QT Syndrome; Male; Middle Aged; Neuregulins; Organic Anion Transporters; Pharmacogenetics; Phosphoproteins; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Piperidines; Polymorphism, Single Nucleotide; RNA-Binding Proteins; Schizophrenia; Thiazoles; Young Adult | 2009 |
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2008 |
The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Pyrimidines; Research Design; Risperidone; Schizophrenia; Schizophrenic Psychology | 2008 |
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Schizophrenia; Severity of Illness Index; Young Adult | 2009 |
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.
Topics: Adult; Buttocks; Cross-Over Studies; Double-Blind Method; Female; Headache; Humans; Injections, Intramuscular; Internationality; Isoxazoles; Male; Middle Aged; Muscle, Skeletal; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Shoulder; Sleep Initiation and Maintenance Disorders | 2009 |
Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Isoxazoles; Male; Mood Disorders; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Severity of Illness Index | 2010 |
Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms.
Topics: Acute Disease; Adult; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Double-Blind Method; Female; Genetic Markers; Genotype; Humans; Isoxazoles; Likelihood Functions; Male; Middle Aged; Odds Ratio; Pharmacogenetics; Piperazines; Piperidines; Polymorphism, Single Nucleotide; Probability; Psychiatric Status Rating Scales; Psychometrics; Schizophrenia; Thiazoles; Treatment Outcome | 2009 |
Independent effect of paliperidone extended release on social functioning beyond its effect on positive and negative symptoms of schizophrenia: a mediation analysis.
Topics: Adult; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Negotiating; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Social Behavior | 2009 |
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypotension, Orthostatic; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Young Adult | 2010 |
Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2010 |
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Severity of Illness Index; Young Adult | 2010 |
Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
Topics: Analysis of Variance; Antipsychotic Agents; Female; Follow-Up Studies; Gene Frequency; Genotype; Humans; Isoxazoles; Male; Piperazines; Piperidines; Polymorphism, Genetic; Receptor, Serotonin, 5-HT2C; Schizophrenia; Thiazoles; Weight Gain | 2010 |
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Patient Satisfaction; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 2010 |
Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Schizophrenia; Time Factors | 2010 |
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Biomarkers, Pharmacological; Brief Psychiatric Rating Scale; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Severity of Illness Index | 2010 |
A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia.
Topics: Acute Disease; Adult; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Pain; Paliperidone Palmitate; Palmitates; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Body Mass Index; Body Weight; Case-Control Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Evidence-Based Medicine; Female; Humans; Injections; Isoxazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2010 |
A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Recurrence; Schizophrenia; Severity of Illness Index; Sex Factors; Time Factors | 2011 |
One-year open-label safety and efficacy study of paliperidone extended-release tablets in patients with schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Humans; Isoxazoles; Paliperidone Palmitate; Schizophrenia; Tablets | 2010 |
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Benzodiazepines; Central Nervous System Stimulants; Cognition Disorders; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Middle Aged; Modafinil; Olanzapine; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dibenzothiazepines; Double-Blind Method; Electrocardiography; Female; Humans; Isoxazoles; Long QT Syndrome; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Quetiapine Fumarate; Schizophrenia; Treatment Outcome | 2011 |
[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study].
Topics: Adolescent; Adult; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Social Behavior; Tablets; Treatment Outcome; Young Adult | 2010 |
A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Drug Delivery Systems; Female; Humans; Isoxazoles; Least-Squares Analysis; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Treatment Outcome; Young Adult | 2011 |
A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Data Interpretation, Statistical; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Dyskinesia, Drug-Induced; Endpoint Determination; Female; Glucose; Heart Diseases; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Prolactin; Psychiatric Status Rating Scales; Risperidone; Sample Size; Schizophrenia; Schizophrenic Psychology; Suicide; Treatment Outcome; Young Adult | 2011 |
Social interaction and drug attitude effectiveness in patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Female; Humans; Interpersonal Relations; Isoxazoles; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Surveys and Questionnaires; Taiwan; Young Adult | 2011 |
Use of paliperidone in elderly patients with schizophrenia and schizoaffective disorder: a prospective open-label short-term pilot study.
Topics: Aged; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pilot Projects; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Schizophrenia | 2011 |
Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Risk; Schizophrenia; Time Factors | 2011 |
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.
Topics: Adolescent; Adult; Aged; Algorithms; Amantadine; Antipsychotic Agents; Benzodiazepines; Clinical Protocols; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Metformin; Middle Aged; Olanzapine; Psychotic Disorders; Schizophrenia; Weight Gain; Zonisamide | 2012 |
Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE).
Topics: Adult; Double-Blind Method; Emergency Medical Services; Female; Hospitalization; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Schizophrenia; Time Factors | 2011 |
Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Cognition Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Mood Disorders; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; Young Adult | 2011 |
Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome | 2011 |
A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Buttocks; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Sleep Initiation and Maintenance Disorders; Treatment Outcome; White People | 2012 |
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.
Topics: Adult; Antipsychotic Agents; Apoptosis Regulatory Proteins; Benzodiazepines; Biomarkers, Pharmacological; Black or African American; Drug Resistance; Genotype; Humans; Isoxazoles; Membrane Proteins; Membrane Transport Proteins; Olanzapine; Piperidines; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, AMPA; Risperidone; Schizophrenia; White People | 2012 |
A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents.
Topics: Acute Disease; Adolescent; Analysis of Variance; Antipsychotic Agents; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Psychology, Adolescent; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2011 |
Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Labeling; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Effects of paliperidone extended release on the symptoms and functioning of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Remission Induction; Schizophrenia; Treatment Outcome | 2012 |
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cognition Disorders; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Olanzapine; Regression Analysis; Schizophrenia; Treatment Outcome; Weight Gain; Young Adult; Zonisamide | 2012 |
Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Middle Aged; Nonlinear Dynamics; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Young Adult | 2012 |
A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Prospective Studies; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psychology; Treatment Failure | 2012 |
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aquaporin 4; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Female; Genetic Association Studies; Humans; Isoxazoles; Male; Middle Aged; Monoamine Oxidase; Olanzapine; Paliperidone Palmitate; Polymorphism, Genetic; Promoter Regions, Genetic; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Smoking; Young Adult | 2012 |
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Delayed-Action Preparations; Female; Glucose Tolerance Test; Humans; Isoxazoles; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Olanzapine; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Triglycerides; Waist Circumference | 2012 |
Flexible dosing with paliperidone ER in the treatment of patients with acutely exacerbated schizophrenia: results from a single-arm, open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Precision Medicine; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Young Adult | 2012 |
Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Cognition Disorders; Delayed-Action Preparations; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Drug Monitoring; Female; Humans; Isoxazoles; Male; Middle Aged; Movement Disorders; Paliperidone Palmitate; Prevalence; Psychiatric Status Rating Scales; Pyrimidines; Republic of Korea; Risperidone; Schizophrenia; Young Adult | 2012 |
The psychopathological characteristics of treatment discontinuation group in 6-month treatment with paliperidone ER.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Drug Substitution; Female; Humans; Isoxazoles; Long-Term Care; Male; Paliperidone Palmitate; Prospective Studies; Psychopathology; Pyrimidines; Schizophrenia; Treatment Outcome | 2012 |
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Female; Humans; India; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Piperazines; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Thiazoles; Time Factors; Treatment Outcome; United States; Young Adult | 2013 |
Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone.
Topics: Adult; Antipsychotic Agents; Attention; Brief Psychiatric Rating Scale; Discrimination Learning; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Neurologic Examination; Neuropsychological Tests; Paliperidone Palmitate; Pattern Recognition, Visual; Psychometrics; Psychomotor Performance; Pyrimidines; Reaction Time; Risperidone; Schizophrenia; Schizophrenic Psychology; Statistics as Topic; Treatment Outcome | 2004 |
Plasma risperidone concentrations during combined treatment with sertraline.
Topics: Adult; Antipsychotic Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Sertraline | 2004 |
Risperidone plasma levels, clinical response and side-effects.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Dose-Response Relationship, Drug; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.
Topics: Administration, Oral; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Binding, Competitive; Brain; Delayed-Action Preparations; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Image Processing, Computer-Assisted; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Positron-Emission Tomography; Pyrimidines; Radioimmunoassay; Receptors, Dopamine D2; Risperidone; Schizophrenia; Scintillation Counting | 2005 |
Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Paroxetine; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Topics: Adult; Antifungal Agents; Antipsychotic Agents; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Female; Genotype; Half-Life; Humans; Isoxazoles; Itraconazole; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia | 2005 |
Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Patient Dropouts; Psychiatric Status Rating Scales; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Tachycardia; Treatment Outcome | 2007 |
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Secondary Prevention; Severity of Illness Index; Treatment Outcome | 2007 |
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Female; Humans; Isoxazoles; Lipids; Male; Middle Aged; Neurologic Examination; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2007 |
Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Blood Glucose; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Humans; Isoxazoles; Lipid Metabolism; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Treatment Outcome | 2007 |
A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Polysomnography; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Sleep Stages; Tablets | 2007 |
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Schizophrenia | 2008 |
Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial.
Topics: Adult; Antipsychotic Agents; Ciliary Neurotrophic Factor; Double-Blind Method; Female; Humans; Isoxazoles; Male; Piperidines; Placebos; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Racial Groups; Schizophrenia; Schizophrenic Psychology | 2008 |
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Piperazines; Piperidines; Prospective Studies; Schizophrenia; Thiazoles; Treatment Outcome | 2008 |
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.
Topics: Acute Disease; Administration, Oral; Adult; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Retention, Psychology; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2008 |
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report.
Topics: Adolescent; Adult; Analgesics; Anticonvulsants; Bipolar Disorder; Carbamazepine; Clinical Trials as Topic; Diazepam; Double-Blind Method; Female; gamma-Aminobutyric Acid; Humans; Isoxazoles; Male; Middle Aged; Mood Disorders; Oxazoles; Oxcarbazepine; Schizophrenia; Valproic Acid | 1983 |
Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations.
Topics: Acute Disease; Adult; Aged; Antipsychotic Agents; Denmark; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Norway; Parkinson Disease, Secondary; Perphenazine; Piperidines; Prevalence; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 1993 |
Risperidone in the treatment of schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Placebos; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1994 |
Symptoms in schizophrenic syndromes in relation to age, sex, duration of illness and number of previous hospitalizations.
Topics: Adult; Age Factors; Age of Onset; Aged; Antipsychotic Agents; Female; Haloperidol; Hospitalization; Hospitals, Psychiatric; Humans; Isoxazoles; Male; Middle Aged; Patient Admission; Piperidines; Risperidone; Ritanserin; Schizophrenia; Schizophrenic Psychology; Sex Factors | 1994 |
Negative symptoms in schizophrenia: assessment of the effect of risperidone.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Single-Blind Method | 1994 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Treatment Outcome | 1994 |
Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol.
Topics: Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia.
Topics: Absorption; Adult; Aged; Aging; Animals; Antipsychotic Agents; Central Nervous System; Cross-Over Studies; Disease Models, Animal; Drug Interactions; Hemodynamics; Humans; Isoxazoles; Neurosecretory Systems; Piperidines; Risperidone; Schizophrenia; Synaptic Transmission; Tissue Distribution | 1994 |
Desmopressin for risperidone-induced enuresis.
Topics: Administration, Intranasal; Adult; Antipsychotic Agents; Deamino Arginine Vasopressin; Double-Blind Method; Enuresis; Female; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Pharmacokinetics of risperidone in chronic schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Cross-Over Studies; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Therapeutic Equivalency | 1994 |
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis.
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Resistance; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Psychoses, Substance-Induced; Risperidone; Schizophrenia; Schizophrenic Psychology; Sex Characteristics | 1994 |
Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride--an 123I-IBZM single photon emission tomography (SPET) study.
Topics: Adult; Antipsychotic Agents; Basal Ganglia; Benzamides; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Female; Humans; Image Processing, Computer-Assisted; Iodine Radioisotopes; Isoxazoles; Male; Middle Aged; Neostriatum; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrrolidines; Remoxipride; Risperidone; Schizophrenia; Tomography, Emission-Computed, Single-Photon | 1995 |
Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1995 |
Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
The negative component in schizophrenia.
Topics: Affective Symptoms; Antipsychotic Agents; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
New pharmacotherapeutic modalities for negative symptoms in psychosis.
Topics: Affective Symptoms; Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Risperidone; Schizophrenia; Schizophrenic Psychology; Syndrome | 1995 |
Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Clopenthixol; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Critique of the Canadian Multicenter Placebo-Controlled Study of Risperidone and Haloperidol.
Topics: Canada; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Research Design; Risperidone; Schizophrenia | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Haloperidol; Humans; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Neurologic Examination; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia | 1993 |
Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dominance, Cerebral; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Evoked Potentials; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology; Social Behavior | 1993 |
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Topics: Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 1993 |
Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 1998 |
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Pyrimidines; Risperidone; Schizophrenia | 1999 |
Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Female; Humans; Isoxazoles; Japan; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Reproducibility of Results; Risperidone; Schizophrenia; Sensitivity and Specificity | 1999 |
Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.
Topics: Acute Disease; Adult; Antipsychotic Agents; Asian People; Drug Administration Schedule; Female; Hospitalization; Humans; Isoxazoles; Male; Paliperidone Palmitate; Patient Readmission; Pharmacogenetics; Prospective Studies; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Taiwan; Treatment Outcome | 2000 |
Effect of risperidone on plasma free 3-methoxy-4-hydroxyphenylglycol (pMHPG) levels in schizophrenic patients: relationship among plasma concentrations of risperidone and 9-hydroxyrisperidone, pMHPG levels, and clinical improvement.
Topics: Adolescent; Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Serotonin Antagonists; Treatment Outcome | 2000 |
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure Liquid; Chronic Disease; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 2001 |
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Observer Variation; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Reproducibility of Results; Risperidone; Schizophrenia; Schizophrenic Psychology; Sweden | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Pathologic; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, X-Ray Computed | 1992 |
Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties.
Topics: Antipsychotic Agents; Dopamine Antagonists; Double-Blind Method; Electrocardiography; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Risperidone; Schizophrenia; Serotonin Antagonists | 1992 |
Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group.
Topics: Antipsychotic Agents; Double-Blind Method; Haloperidol; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1992 |
Risperidone: clinical development: north American results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Humans; Isoxazoles; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 1992 |
Risperidone: clinical safety and efficacy in schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1992 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Receptors, Glutamate; Receptors, Neurotransmitter; Receptors, Serotonin; Remoxipride; Risperidone; Schizophrenia; Serotonin Antagonists; Sulpiride | 1991 |
Thymosthenic agents, a novel approach in the treatment of schizophrenia.
Topics: Brain; Butyrophenones; Humans; Isoxazoles; Piperidines; Pyrimidinones; Randomized Controlled Trials as Topic; Receptors, Serotonin; Risperidone; Ritanserin; Schizophrenia; Schizophrenic Psychology; Serotonin Antagonists | 1989 |
Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
Topics: Adult; Aminocaproates; Brain; Clinical Trials as Topic; Double-Blind Method; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Humans; Isoxazoles; Male; Middle Aged; Receptors, GABA-A; Schizophrenia; Vigabatrin | 1987 |
179 other study(ies) available for isoxazoles and Schizophrenia
| Article | Year |
|---|---|
How Would You Like to Take Your Medicine 2 Times a Year? Paliperidone Palmitate Every 6 Months for the Maintenance Treatment of Schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Schizophrenia | 2022 |
Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Chemistry, Pharmaceutical; Dizocilpine Maleate; Drug Carriers; Emulsions; Excipients; Humans; Isoxazoles; Locomotion; Male; Models, Animal; Particle Size; Piperidines; Rats; Schizophrenia; Solubility; Surface-Active Agents; Suspensions; Tablets | 2020 |
Alpha 7 nicotinic receptor agonist and positive allosteric modulators improved social and molecular deficits of MK-801 model of schizophrenia in rats.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Avoidance Learning; Clozapine; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Models, Animal; Dizocilpine Maleate; Glycogen Synthase Kinase 3 beta; Isoxazoles; Male; Phenylurea Compounds; Prefrontal Cortex; Proto-Oncogene Proteins c-akt; Pyridazines; Pyrroles; Rats; Rats, Wistar; Schizophrenia; Signal Transduction; Social Interaction; Treatment Outcome | 2020 |
Inhibition of voltage-dependent K
Topics: Antipsychotic Agents; Coronary Vessels; Isoxazoles; Membrane Potentials; Myocytes, Smooth Muscle; Piperidines; Potassium Channel Blockers; Schizophrenia; Voltage-Dependent Anion Channels | 2020 |
α7 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Hippocampus; Isoxazoles; Male; Nicotinic Agonists; Phenylurea Compounds; Pyridazines; Pyrroles; Rats; Rats, Wistar; Recognition, Psychology; Schizophrenia | 2021 |
Explainable AI enables clinical trial patient selection to retrospectively improve treatment effects in schizophrenia.
Topics: Antipsychotic Agents; Artificial Intelligence; Bayes Theorem; Humans; Isoxazoles; Patient Selection; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Retrospective Studies; Schizophrenia; Treatment Outcome | 2021 |
Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
Topics: Animals; Animals, Newborn; Antipsychotic Agents; Cannabidiol; Cell Culture Techniques; Cerebral Cortex; Disease Models, Animal; Female; Isoxazoles; Male; Neurons; Piperidines; Rats; Rats, Sprague-Dawley; Schizophrenia; Sex Characteristics | 2021 |
The Effect of Chronic Iloperidone Treatment on Cytochrome P450 Expression and Activity in the Rat Liver: Involvement of Neuroendocrine Mechanisms.
Topics: Animals; Antipsychotic Agents; Cytochrome P-450 Enzyme System; Gene Expression; Isoxazoles; Liver; Male; Microsomes, Liver; Piperidines; Rats; Rats, Wistar; Schizophrenia | 2021 |
[Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia].
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2019 |
Safety of paliperidone extended-release in patients with schizophrenia or schizoaffective disorder and hepatic disease.
Topics: Antipsychotic Agents; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Isoxazoles; Liver Diseases; Liver Function Tests; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Schizophrenia; Treatment Outcome | 2014 |
Paliperidone in the treatment of Tourette's syndrome with comorbid schizophrenia.
Topics: Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Tourette Syndrome | 2013 |
Using paliperidone as a monotherapeutic agent on a schizophrenic patient with cirrhosis of the liver.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Liver Cirrhosis; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2013 |
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Injections; Isoxazoles; Medication Adherence; Olanzapine; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia | 2013 |
Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; Japan; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Pyrimidines; Regression Analysis; Risperidone; Schizophrenia; Young Adult | 2013 |
Successful use of paliperidone in a clozapine-resistant schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2013 |
Paliperidone-induced tardive dystonia: a case report.
Topics: Adult; Antipsychotic Agents; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2013 |
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Czech Republic; Decision Support Techniques; Delayed-Action Preparations; Drug Costs; Economics, Pharmaceutical; Female; Humans; Isoxazoles; Male; Multivariate Analysis; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult | 2013 |
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Decision Support Techniques; Delayed-Action Preparations; Drug Costs; Economics, Pharmaceutical; Female; Finland; Humans; Isoxazoles; Male; Multivariate Analysis; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult | 2013 |
Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Germany; Health Care Costs; Humans; Isoxazoles; Markov Chains; Paliperidone Palmitate; Palmitates; Schizophrenia; Secondary Prevention | 2013 |
Validation of an economic model of paliperidone palmitate for chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Decision Trees; Delayed-Action Preparations; Hospitalization; Humans; Isoxazoles; Models, Economic; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Recurrence; Reproducibility of Results; Schizophrenia; Sweden | 2013 |
Interaction between paliperidone and carbamazepine.
Topics: Antimanic Agents; Antipsychotic Agents; Carbamazepine; Drug Interactions; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2013 |
Paliperidone palmitate long-acting injection--prospective year-long follow-up of use in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delayed-Action Preparations; Female; Follow-Up Studies; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Psychotic Disorders; Pyrimidines; Schizophrenia; Treatment Outcome; Young Adult | 2014 |
Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Schizophrenia | 2013 |
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Cost of Illness; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Costs; Female; Haloperidol; Health Care Costs; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Models, Econometric; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Sweden | 2014 |
Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Bipolar Disorder; Cohort Studies; Delayed-Action Preparations; Drug Monitoring; Electronic Health Records; Female; Follow-Up Studies; Hospitals, Urban; Humans; Isoxazoles; Length of Stay; London; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Patient Acceptance of Health Care; Patient Compliance; Psychotic Disorders; Recurrence; Schizophrenia; Young Adult | 2014 |
[Maintenance treatment of schizophrenia with paliperidone palmitate (xeplion): a naturalistic study].
Topics: Adult; Antipsychotic Agents; Disease Progression; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2013 |
Paliperidone extended-release in patients with non-acute schizophrenia previously unsuccessfully treated with other oral antipsychotics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Anxiety; Delayed-Action Preparations; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Schizophrenia; Sleep Initiation and Maintenance Disorders | 2014 |
Pisa syndrome induced by paliperidone.
Topics: Adolescent; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dystonia; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Syndrome | 2014 |
Possible paliperidone-related pons infarction.
Topics: Adult; Antipsychotic Agents; Brain Stem Infarctions; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pons; Pyrimidines; Schizophrenia; Taiwan | 2014 |
Clinical effectiveness and resource utilization of paliperidone ER for schizophrenia: Pharmacoepidemiologic International Longitudinal Antipsychotic Registry (PILAR).
Topics: Administration, Oral; Adult; Ambulatory Care; Antipsychotic Agents; Emergency Medical Services; Female; Hospitalization; Humans; Isoxazoles; Longitudinal Studies; Male; Middle Aged; Paliperidone Palmitate; Patient Satisfaction; Practice Patterns, Physicians'; Prospective Studies; Psychiatric Status Rating Scales; Pyrimidines; Quality of Life; Registries; Retrospective Studies; Schizophrenia; Treatment Outcome | 2014 |
A case of priapism associated with paliperidone.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Paliperidone Palmitate; Priapism; Pyrimidines; Schizophrenia | 2014 |
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States | 2014 |
Parenteral thermo-sensitive organogel for schizophrenia therapy, in vitro and in vivo evaluation.
Topics: Animals; Antipsychotic Agents; Coumarins; Drug Delivery Systems; Fatty Acids; Gels; Isoxazoles; Male; Mice, Nude; Paliperidone Palmitate; Phase Transition; Pyrimidines; Rats, Sprague-Dawley; Schizophrenia; Soybean Oil; Thiazoles; Transition Temperature; Viscosity | 2014 |
Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Blood Chemical Analysis; Chromatography, Liquid; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prospective Studies; Pyrimidines; Risperidone; Schizophrenia; Severity of Illness Index; Tandem Mass Spectrometry; Treatment Outcome | 2014 |
No change of the lipid profile under the control of ApoE gene polymorphism in schizophrenics under paliperidone treatment.
Topics: Adult; Antipsychotic Agents; Apolipoproteins E; Female; Genotype; Humans; Isoxazoles; Lipids; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Surveys and Questionnaires; Young Adult | 2014 |
Obsessive-compulsive symptoms induced by long-acting injectable paliperidone in a patient with schizophrenia: a case report.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Isoxazoles; Male; Obsessive-Compulsive Disorder; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2014 |
One-year treatment continuation in patients switched to paliperidone palmitate: a retrospective study.
Topics: Adult; Female; Humans; Isoxazoles; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Palmitates; Retrospective Studies; Risk Factors; Schizophrenia; Young Adult | 2014 |
Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Isoxazoles; Male; Obesity; Paliperidone Palmitate; Palmitates; Pyrimidines; Schizophrenia; Time Factors | 2015 |
Understanding responder neurobiology in schizophrenia using a quantitative systems pharmacology model: application to iloperidone.
Topics: Antipsychotic Agents; Computer Simulation; Genotype; Humans; Isoxazoles; Models, Biological; Molecular Targeted Therapy; Neurobiology; Pharmacogenetics; Piperazines; Piperidines; Schizophrenia; Thiazoles | 2015 |
Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Cohort Studies; Costs and Cost Analysis; Emergency Service, Hospital; Endpoint Determination; Female; Humans; Isoxazoles; Length of Stay; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Patient Readmission; Propensity Score; Retrospective Studies; Schizophrenia | 2015 |
Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Child; Child, Preschool; Genetic Association Studies; Humans; Isoxazoles; Middle Aged; Neuregulin-1; Paliperidone Palmitate; Polymorphism, Single Nucleotide; Pyrimidines; Receptor, ErbB-4; Schizophrenia; Young Adult | 2015 |
Paliperidone palmitate for refractory and clozapine-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Schizophrenia; Young Adult | 2015 |
Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits.
Topics: Acoustic Stimulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Auditory Perception; Choline; Disease Models, Animal; Female; Heterozygote; Hippocampus; Isoxazoles; Male; Mice; Mice, Inbred C3H; Mice, Inbred DBA; Mice, Transgenic; Phenylurea Compounds; Schizophrenia; Sensory Gating | 2015 |
Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia.
Topics: Early Medical Intervention; Female; Humans; Isoxazoles; Male; Palmitates; Risperidone; Schizophrenia; Secondary Prevention | 2015 |
A Novel Multisensory Integration Task Reveals Robust Deficits in Rodent Models of Schizophrenia: Converging Evidence for Remediation via Nicotinic Receptor Stimulation of Inhibitory Transmission in the Prefrontal Cortex.
Topics: Animals; gamma-Aminobutyric Acid; In Vitro Techniques; Isoxazoles; Ketamine; Male; Mice; Mice, Inbred C57BL; Nicotinic Agonists; Prefrontal Cortex; Psychomotor Performance; Pyrrolidines; Rats; Rats, Long-Evans; Receptors, Nicotinic; Schizophrenia; Schizophrenic Psychology; Synaptic Transmission | 2016 |
Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Topics: Acetylcholine; Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Attention; Cognition; Cognitive Dysfunction; Dizocilpine Maleate; Isoxazoles; Male; Memory Disorders; Memory, Short-Term; Nicotinic Agonists; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Sensory Gating | 2017 |
Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Double-Blind Method; Female; Hospitalization; Humans; Isoxazoles; Male; Medical Audit; Middle Aged; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; United States | 2008 |
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Benzodiazepines; Biotransformation; Cytochrome P-450 CYP2D6; Drug Monitoring; Female; Humans; Inpatients; Isoxazoles; Male; Mental Disorders; Middle Aged; Olanzapine; Paliperidone Palmitate; Pyrimidines; Regression Analysis; Risperidone; Schizophrenia; Young Adult | 2008 |
Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study.
Topics: Adult; Age Factors; Aged; Alzheimer Disease; Antipsychotic Agents; Biological Availability; Body Weight; Female; Humans; Isoxazoles; Male; Metabolic Clearance Rate; Middle Aged; Models, Chemical; Models, Statistical; Paliperidone Palmitate; Pyrimidines; Randomized Controlled Trials as Topic; Risperidone; Sample Size; Sampling Studies; Schizophrenia | 2008 |
What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
Topics: Antipsychotic Agents; Capsules; Decision Making; Delayed-Action Preparations; Humans; Isoxazoles; Mood Disorders; Paliperidone Palmitate; Pyrimidines; Receptors, Dopamine; Schizophrenia | 2008 |
Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Attitude of Health Personnel; Female; Humans; Interpersonal Relations; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Reproducibility of Results; Schizophrenia; Schizophrenic Psychology | 2009 |
Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Case-Control Studies; Cross-Sectional Studies; Dopamine Antagonists; Female; Humans; Isoxazoles; Male; Middle Aged; Ontario; Paliperidone Palmitate; Positron-Emission Tomography; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Raclopride; Receptors, Dopamine D2; Risperidone; Schizophrenia; Treatment Outcome | 2009 |
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Female; Genotype; Humans; Isoxazoles; Male; Oligonucleotide Array Sequence Analysis; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Regression Analysis; Risperidone; Schizophrenia | 2009 |
Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; DNA; Dose-Response Relationship, Drug; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2010 |
Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Asian People; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Isoxazoles; Korea; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Pyrimidines; Risperidone; Schizophrenia | 2009 |
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; Delayed-Action Preparations; Dyskinesia, Drug-Induced; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome; White People | 2009 |
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Anxiety; Cognition; Data Interpretation, Statistical; Depression; Female; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2010 |
Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report.
Topics: Adolescent; Antipsychotic Agents; Humans; Isoxazoles; Male; Obsessive-Compulsive Disorder; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2009 |
Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
Topics: Animals; Antipsychotic Agents; D-Amino-Acid Oxidase; Enzyme Activators; Genome, Human; Humans; Isoxazoles; Pyrazoles; Pyrroles; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Thiophenes | 2009 |
Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Bayes Theorem; Chemistry, Pharmaceutical; Clinical Trials as Topic; Computer Simulation; Data Collection; Delayed-Action Preparations; Drug Administration Schedule; Drug Interactions; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Models, Biological; Paliperidone Palmitate; Pyrimidines; Retrospective Studies; Schizophrenia; Young Adult | 2009 |
In brief: Injectable paliperidone palmitate for schizophrenia.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Drug Costs; Humans; Injections; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2009 |
Paliperidone overdose in a patient with schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Substance Withdrawal Syndrome | 2010 |
Possible neuroleptic malignant syndrome during paliperidone administration: a case report.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Young Adult | 2010 |
[Successful quetiapine therapy in psychotic patients with mood elevation].
Topics: Adult; Affect; Antipsychotic Agents; Dibenzothiazepines; Drug Therapy, Combination; Euphoria; Female; Humans; Isoxazoles; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Weight Gain | 2009 |
Intramuscular paliperidone palmitate.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Humans; Injections, Intramuscular; Isoxazoles; Longitudinal Studies; Paliperidone Palmitate; Palmitates; Psychiatric Status Rating Scales; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2010 |
Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
Topics: Adult; Antipsychotic Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Isoxazoles; Liver Function Tests; Paliperidone Palmitate; Pyrimidines; Reference Values; Risperidone; Schizophrenia | 2010 |
Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Pyrimidines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Time Factors | 2010 |
Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Drug Approval; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Iloperidone (Fanapt)--another second-generation antipsychotic.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2010 |
Manic symptoms induced by paliperidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Female; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2010 |
The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Mutation; Paliperidone Palmitate; Pyrimidines; Risperidone; Sample Size; Schizophrenia; Treatment Outcome | 2010 |
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2010 |
Studies on the acute toxicity, pharmacokinetics and pharmacodynamics of paliperidone derivatives--comparison to paliperidone and risperidone in mice and rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Electrocardiography; Excitatory Amino Acid Antagonists; Female; Heart; Heart Rate; Hyperkinesis; Isoxazoles; Lethal Dose 50; Male; Maximum Tolerated Dose; Mice; Mice, Inbred Strains; Paliperidone Palmitate; Pyrimidines; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Toxicity Tests, Acute | 2010 |
Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia.
Topics: Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Estrous Cycle; Exploratory Behavior; Female; GABA-A Receptor Agonists; Isoxazoles; Motor Activity; Phencyclidine; Rats; Receptors, GABA-A; Recognition, Psychology; Schizophrenia; Schizophrenic Psychology; Time Factors | 2011 |
Paliperidone-induced dystonic Dysphagia.
Topics: Adolescent; Antipsychotic Agents; Deglutition Disorders; Dystonia; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2010 |
[Non-fatal paliperidone overdose: a case report].
Topics: Adult; Antipsychotic Agents; Drug Overdose; Female; Hospitalization; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Treatment Outcome | 2010 |
Paliperidone-associated atypical neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Middle Aged; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2011 |
Atypical antipsychotics: the two new arrivals.
Topics: Antipsychotic Agents; Bipolar Disorder; Dibenzocycloheptenes; Drug Approval; Heterocyclic Compounds, 4 or More Rings; Humans; Isoxazoles; Piperidines; Safety; Schizophrenia; Treatment Outcome; United States; United States Food and Drug Administration | 2011 |
Iloperidone: Does it have a meaningful place in therapy?
Topics: Antipsychotic Agents; Drug Administration Schedule; Drug Costs; Humans; Isoxazoles; Piperidines; Schizophrenia | 2011 |
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Databases as Topic; Delayed-Action Preparations; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Paliperidone Palmitate; Propensity Score; Psychiatric Status Rating Scales; Pyrimidines; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2011 |
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Central Nervous System Stimulants; Disease Models, Animal; Drug Interactions; Female; Isoxazoles; Motor Activity; Paliperidone Palmitate; Poly I-C; Pregnancy; Prenatal Exposure Delayed Effects; Pyrimidines; Rats; Rats, Sprague-Dawley; Risperidone; Schizophrenia; Time Factors | 2011 |
Update on newer antipsychotic drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Child; Clinical Trials as Topic; Dibenzocycloheptenes; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Isoindoles; Isoxazoles; Lurasidone Hydrochloride; Male; Piperidines; Pregnancy; Schizophrenia; Thiazoles; Treatment Outcome | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
MultiSimplex optimization of chromatographic separation and dansyl derivatization conditions in the ultra performance liquid chromatography-tandem mass spectrometry analysis of risperidone, 9-hydroxyrisperidone, monoamine and amino acid neurotransmitters
Topics: Biogenic Monoamines; Case-Control Studies; Chromatography, High Pressure Liquid; Dansyl Compounds; Humans; Isoxazoles; Multivariate Analysis; Neurotransmitter Agents; Paliperidone Palmitate; Pyrimidines; Reproducibility of Results; Risperidone; Schizophrenia; Sensitivity and Specificity; Tandem Mass Spectrometry | 2011 |
Paliperidone-induced obsessive symptoms.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Obsessive Behavior; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2011 |
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Extracellular Space; Female; Glutamic Acid; Isoxazoles; Male; Maternal Exposure; Paliperidone Palmitate; Poly I-C; Prefrontal Cortex; Pregnancy; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Risperidone; Schizophrenia | 2011 |
The chimeric gene CHRFAM7A, a partial duplication of the CHRNA7 gene, is a dominant negative regulator of α7*nAChR function.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Bungarotoxins; Cell Line, Tumor; Cloning, Molecular; Electrophysiological Phenomena; Female; Genes, Duplicate; Genetic Linkage; Humans; Isoxazoles; Ligands; Multigene Family; Oocytes; Patch-Clamp Techniques; Phenylurea Compounds; Protein Binding; Receptors, Nicotinic; Reverse Transcriptase Polymerase Chain Reaction; RNA; Schizophrenia; Smoking; Transfection; Xenopus laevis | 2011 |
Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone.
Topics: Adult; Antipsychotic Agents; Brief Psychiatric Rating Scale; Drug Monitoring; Female; Genotype; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Pyrimidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome; Young Adult | 2011 |
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2011 |
Manic symptoms during a switch from risperidone to paliperidone: a case report.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Follow-Up Studies; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2011 |
Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone.
Topics: Administration, Oral; Adult; Anaphylaxis; Antipsychotic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Isoxazoles; Male; Paliperidone Palmitate; Palmitates; Risperidone; Schizophrenia; Suspensions | 2012 |
[Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection].
Topics: Administration, Ophthalmic; Antipsychotic Agents; Delayed-Action Preparations; Drug Substitution; Humans; Injections; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Receptors, Adrenergic, alpha-2; Recurrence; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Tardive Tourette-like syndrome in a patient treated with paliperidone.
Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Young Adult | 2011 |
Effects of the selective kainate receptor antagonist ACET on altered sensorimotor gating in a genetic model of reduced NMDA receptor function.
Topics: Alanine; Animals; Antipsychotic Agents; Carrier Proteins; Disease Models, Animal; Gene Knockdown Techniques; Isoxazoles; Mice; Nerve Tissue Proteins; Propionates; Receptors, Kainic Acid; Receptors, N-Methyl-D-Aspartate; Schizophrenia; Uracil | 2012 |
A change from risperidone long acting injection to paliperidone palmitate in an elderly patient--a cautionary tale.
Topics: Aged; Antipsychotic Agents; Female; Humans; Isoxazoles; Paliperidone Palmitate; Palmitates; Recurrence; Risperidone; Schizophrenia; Treatment Failure | 2012 |
Catatonia and encephalopathy associated with paliperidone palmitate.
Topics: Aged; Antipsychotic Agents; Catatonia; Female; Humans; Isoxazoles; Lorazepam; Male; Neuroleptic Malignant Syndrome; Palmitates; Psychotic Disorders; Pyrimidines; Schizophrenia | 2012 |
Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clinical Trials as Topic; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Palmitates; Placebos; Recurrence; Schizophrenia; Treatment Failure; Treatment Outcome | 2012 |
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Drug Substitution; Female; Health Resources; Humans; Injections; Isoxazoles; Male; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Palmitates; Quality-Adjusted Life Years; Recurrence; Risperidone; Schizophrenia; Sweden | 2012 |
The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Personal Satisfaction; Psychiatric Status Rating Scales; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index; Treatment Outcome | 2012 |
Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Double-Blind Method; Humans; Injections, Intramuscular; Isoxazoles; Multicenter Studies as Topic; Paliperidone Palmitate; Palmitates; Randomized Controlled Trials as Topic; Schizophrenia | 2012 |
Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients.
Topics: Adult; Alleles; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Isoxazoles; Japan; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Young Adult | 2012 |
Relationship between inflammation and metabolic syndrome following treatment with paliperidone for schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Delayed-Action Preparations; Female; Humans; Inflammation; Isoxazoles; Leukocyte Count; Male; Metabolic Syndrome; Middle Aged; Paliperidone Palmitate; Pyrimidines; Schizophrenia | 2012 |
Pharmacokinetics of oral D-serine in D-amino acid oxidase knockout mice.
Topics: Animals; Brain; D-Amino-Acid Oxidase; Female; Half-Life; Humans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Schizophrenia; Serine | 2012 |
A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Gas Chromatography-Mass Spectrometry; Humans; Injections, Intramuscular; Isoxazoles; Long-Term Care; Male; Middle Aged; Paliperidone Palmitate; Positron-Emission Tomography; Psychiatric Status Rating Scales; Pyrimidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2012 |
The cost-effectiveness of paliperidone extended release in Spain.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Delayed-Action Preparations; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Qualitative Research; Quality-Adjusted Life Years; Schizophrenia; Spain | 2012 |
Paliperidone as an alternative for risperidone in a case of schizophrenia with retrograde ejaculation.
Topics: Adult; Antipsychotic Agents; Ejaculation; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Sexual Dysfunction, Physiological | 2012 |
Possible paliperidone-induced neuroleptic malignant syndrome: a case report.
Topics: Antipsychotic Agents; Creatine Kinase; Humans; Isoxazoles; Male; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Tomography, X-Ray Computed; Young Adult | 2012 |
Improvements in micturition and urinary retention after switching from amisulpiride to paliperidone in a schizophrenic patient.
Topics: Amisulpride; Antipsychotic Agents; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Retreatment; Schizophrenia; Sulpiride; Treatment Outcome; Urinary Retention; Urination | 2012 |
Treating residual insomnia in schizophrenia: examining the options.
Topics: Antipsychotic Agents; Central Nervous System Depressants; Humans; Isoxazoles; Melatonin; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Sleep Initiation and Maintenance Disorders | 2013 |
Paliperidone-related Pisa syndrome.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Substitution; Dyskinesia, Drug-Induced; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2013 |
Iloperidone-induced retrograde ejaculation.
Topics: Antipsychotic Agents; Capgras Syndrome; Ejaculation; Humans; Isoxazoles; Male; Piperidines; Schizophrenia; Sexual Dysfunctions, Psychological; Young Adult | 2013 |
Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Genotype; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Phenotype; Pyrimidines; Risperidone; Schizophrenia; White People | 2002 |
Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genotype; Half-Life; Humans; Hydroxylation; Isoxazoles; Japan; Male; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia; Stereoisomerism | 2003 |
Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Topics: Adult; Analysis of Variance; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Isoxazoles; Japan; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2003 |
Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Genes, MDR; Genotype; Humans; Isoxazoles; Male; Middle Aged; Mutation; Paliperidone Palmitate; Polymorphism, Genetic; Pyrimidines; Risperidone; Schizophrenia | 2004 |
Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Caffeine; Catecholamines; Central Nervous System Stimulants; Cotinine; Cues; Cytochrome P-450 CYP2D6; Female; Homovanillic Acid; Humans; Isoxazoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Smoking | 2005 |
KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.
Topics: Animals; Antipsychotic Agents; Body Temperature; Catalepsy; Cell Line; Dopamine Uptake Inhibitors; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Ion Channels; Isoxazoles; Male; Mice; Mice, Inbred ICR; Piperazines; Postural Balance; Prolactin; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D1; Receptors, Dopamine D3; Receptors, Dopamine D4; Reflex, Startle; Schizophrenia; Schizophrenic Psychology; Serotonin Receptor Agonists; Spiperone; Swimming | 2005 |
Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Area Under Curve; Asian People; China; Female; Humans; Isoxazoles; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2006 |
A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Carbon Radioisotopes; Corpus Striatum; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Positron-Emission Tomography; Prolactin; Psychotic Disorders; Pyrimidines; Raclopride; Receptors, Dopamine D2; Risperidone; Schizophrenia | 2006 |
Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome | 2006 |
[Paliperidone].
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Psychotic Disorders; Pyrimidines; Schizophrenia | 2006 |
Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; China; Female; Gene Frequency; Humans; Isoxazoles; Linkage Disequilibrium; Male; Organic Anion Transporters; Paliperidone Palmitate; Polymorphism, Genetic; Psychiatric Status Rating Scales; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 2006 |
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
Topics: Adult; Antipsychotic Agents; Biotransformation; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Pyrimidines; Risperidone; Schizophrenia | 2006 |
Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Drug Interactions; Female; Homovanillic Acid; Humans; Isoxazoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychomotor Agitation; Pyrimidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Valproic Acid | 2007 |
Paliperidone (Invega) for schizophrenia.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Humans; Isoxazoles; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Treatment Outcome | 2007 |
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Catecholamines; Chromatography, High Pressure Liquid; Female; Genotype; Humans; Immunoenzyme Techniques; Isoxazoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Norepinephrine Plasma Membrane Transport Proteins; Paliperidone Palmitate; Polymorphism, Genetic; Pyrimidines; Risperidone; Schizophrenia | 2007 |
Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Paliperidone Palmitate; Prolactin; Pyrimidines; Risperidone; Schizophrenia | 2007 |
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Cytochrome P-450 CYP2D6; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Polymorphism, Genetic; Prolactin; Pyrimidines; Risperidone; Schizophrenia | 2007 |
Molecule of the month. Paliperidone.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Headache; Humans; Isoxazoles; Molecular Structure; Paliperidone Palmitate; Pyrimidines; Schizophrenia; Sleep Initiation and Maintenance Disorders; Tablets | 2007 |
Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Brain Chemistry; Data Interpretation, Statistical; Delayed-Action Preparations; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Isoxazoles; Male; Neostriatum; Paliperidone Palmitate; Positron-Emission Tomography; Psychiatric Status Rating Scales; Pyrimidines; Pyrrolidines; Raclopride; Radiopharmaceuticals; Receptors, Dopamine D2; Salicylamides; Schizophrenia | 2008 |
Paliperidone: new drug. Just a metabolite of risperidone, a neuroleptic soon off-patent.
Topics: Antipsychotic Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Isoxazoles; Pyrimidines; Risperidone; Schizophrenia; Treatment Outcome | 2007 |
Paliperidone: An improvement over risperidone?
Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Humans; Isoxazoles; Marketing; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2008 |
New advances in the treatment of schizophrenia. Introduction.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Schizophrenia | 2008 |
Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Endpoint Determination; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Psychotic Disorders; Randomized Controlled Trials as Topic; Schizophrenia | 2008 |
Adverse reaction reporting and new antipsychotics.
Topics: Agranulocytosis; Anemia, Aplastic; Antipsychotic Agents; Clozapine; Drug Monitoring; Humans; Isoxazoles; Neutropenia; Piperidines; Remoxipride; Risperidone; Schizophrenia | 1993 |
Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone.
Topics: Adult; Antipsychotic Agents; Benzamides; Brain; Brain Mapping; Contrast Media; Dopamine D2 Receptor Antagonists; Humans; Iodine Radioisotopes; Isoxazoles; Male; Piperidines; Psychiatric Status Rating Scales; Pyrrolidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Schizophrenic Psychology; Tomography, Emission-Computed, Single-Photon | 1993 |
Risperidone and remoxipride for schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Isoxazoles; Piperidines; Remoxipride; Risperidone; Schizophrenia | 1993 |
Risperidone for chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone.
Topics: Adult; Clinical Trials as Topic; Humans; Isoxazoles; Multicenter Studies as Topic; Piperidines; Placebos; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1994 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor Antagonists; Haloperidol; Humans; In Vitro Techniques; Isoxazoles; Lysergic Acid Diethylamide; Motor Activity; Neostriatum; Oxygen Consumption; Piperidines; Rats; Risperidone; Schizophrenia; Serotonin Antagonists; Species Specificity; Tryptamines | 1994 |
Schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone for schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Dystonic reaction and relapse with clozapine discontinuation and risperidone intiation.
Topics: Adult; Antipsychotic Agents; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Dystonia; Humans; Isoxazoles; Male; Neurologic Examination; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Substance Withdrawal Syndrome | 1994 |
Risperidone: a novel antipsychotic medication.
Topics: Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
New drug offers hope for people with schizophrenia.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
The effect of risperidone and ritanserin on human IgG and IgM synthesis in vitro.
Topics: Antipsychotic Agents; B-Lymphocytes; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Immunoglobulin M; In Vitro Techniques; Isoxazoles; Monocytes; Piperidines; Pokeweed Mitogens; Risperidone; Ritanserin; Schizophrenia | 1994 |
Response to clozapine as a predictor of risperidone response in schizophrenia.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Isoxazoles; Piperidines; Receptors, Dopamine; Risperidone; Schizophrenia; Treatment Outcome | 1994 |
The pharmacokinetics of risperidone in humans: a summary.
Topics: Aged; Animals; Antipsychotic Agents; Biotransformation; Dogs; Half-Life; Humans; Isoxazoles; Liver Cirrhosis; Male; Paliperidone Palmitate; Piperidines; Pyrimidines; Rats; Reference Values; Renal Insufficiency; Risperidone; Schizophrenia | 1994 |
Risperidone: new horizons for the schizophrenic patient. 9th World Congress of Psychiatry of the World Psychiatric Association, Rio de Janeiro, June 1993.
Topics: Antipsychotic Agents; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Antipsychotic Agents; Drug Therapy, Combination; Fluvoxamine; Humans; Isoxazoles; Male; Obsessive-Compulsive Disorder; Piperidines; Receptors, Serotonin; Risperidone; Schizophrenia; Schizophrenic Psychology; Serotonin | 1994 |
Risperidone in adolescents.
Topics: Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Isoxazoles; Male; Piperidines; Psychotic Disorders; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Risperidone treatment for severe negative symptoms.
Topics: Adult; Antipsychotic Agents; Clonazepam; Depressive Disorder; Drug Therapy, Combination; Humans; Isoxazoles; Male; Patient Readmission; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Risperidone's cost.
Topics: Antipsychotic Agents; Delivery of Health Care; Health Services Accessibility; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1994 |
High-dose antipsychotic medication.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Effects of risperidone on phencyclidine-induced behaviors: comparison with haloperidol and ritanserin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Chromatography, High Pressure Liquid; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Frontal Lobe; Haloperidol; Homovanillic Acid; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Isoxazoles; Locomotion; Male; Phencyclidine; Piperidines; Random Allocation; Rats; Rats, Wistar; Risperidone; Ritanserin; Schizophrenia; Serotonin; Stereotyped Behavior | 1994 |
Novel neuroleptics in schizophrenia: theory and clinical relevance.
Topics: Antipsychotic Agents; Brain; Clozapine; Humans; Isoxazoles; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Schizophrenia and severe tardive dyskinesia responsive to risperidone.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Isoxazoles; Neurologic Examination; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Schizophrenic Psychology | 1994 |
Addressing emerging social needs of patients treated with new neuroleptics.
Topics: Adult; Antipsychotic Agents; Clozapine; Female; Humans; Isoxazoles; Male; Middle Aged; Nursing Assessment; Piperidines; Psychiatric Nursing; Risperidone; Schizophrenia; Socialization | 1994 |
Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Binding Sites; Brain; Female; Humans; Isoxazoles; Male; Middle Aged; Piperidines; Receptors, Dopamine D2; Receptors, Serotonin; Risperidone; Schizophrenia; Tomography, Emission-Computed | 1995 |
Recent developments in antipsychotic therapy. Introduction.
Topics: Antipsychotic Agents; Clozapine; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1995 |
Risperidone in childhood schizophrenia.
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Drug Therapy, Combination; Humans; Isoxazoles; Male; Methylphenidate; Piperidines; Risperidone; Schizophrenia; Treatment Outcome | 1995 |
Effects of concomitant risperidone and lithium treatment.
Topics: Antipsychotic Agents; Confusion; Creatine Kinase; Drug Therapy, Combination; Fever; Humans; Isoxazoles; Lithium Carbonate; Neuroleptic Malignant Syndrome; Piperidines; Risperidone; Schizophrenia | 1995 |
Behavioral stimulation associated with risperidone initiation.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Anxiety; Benzodiazepines; Confusion; Female; Humans; Isoxazoles; Middle Aged; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Substance Withdrawal Syndrome | 1995 |
Switching patients from clozapine to risperidone therapy.
Topics: Antipsychotic Agents; Clonazepam; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoxazoles; Lorazepam; Piperidines; Risperidone; Schizophrenia; Substance Withdrawal Syndrome | 1995 |
Risperidone-induced prolactin elevations in premenopausal women with schizophrenia.
Topics: Antipsychotic Agents; Female; Humans; Hyperprolactinemia; Isoxazoles; Piperidines; Premenopause; Prolactin; Risperidone; Schizophrenia | 1995 |
Prescribing risperidone.
Topics: Antipsychotic Agents; Cost-Benefit Analysis; Drug Prescriptions; Financing, Government; Health Care Rationing; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Virginia | 1995 |
Risperidone for the treatment of schizophrenia: does it have a niche?
Topics: Dopamine Antagonists; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology | 1995 |
Reversible neutropenia during a cold: possible involvement of risperidone? A case report.
Topics: Adult; Antipsychotic Agents; Cold Temperature; Female; Humans; Influenza, Human; Isoxazoles; Neutropenia; Piperidines; Risperidone; Schizophrenia | 1995 |
Risperidone for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Humans; Isoxazoles; Male; Piperidines; Risperidone; Schizophrenia; Treatment Outcome | 1995 |
Clinical implications of clozapine discontinuation: report of an NIMH workshop.
Topics: Antipsychotic Agents; Clozapine; Drug Administration Schedule; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Schizophrenic Psychology; Substance Withdrawal Syndrome; United States; United States Food and Drug Administration | 1995 |
Unexpected dystonia while changing from clozapine to risperidone.
Topics: Adult; Antipsychotic Agents; Clozapine; Dystonia; Humans; Isoxazoles; Male; Piperidines; Risperidone; Schizophrenia | 1995 |
Concomitant use of thioridazine with risperidone.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia; Thioridazine | 1995 |
The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.
Topics: Adult; Akathisia, Drug-Induced; Basal Ganglia Diseases; Humans; Isoxazoles; Male; Piperidines; Receptors, Dopamine D2; Risperidone; Schizophrenia; Tomography, Emission-Computed | 1995 |
Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics?
Topics: Adult; Antipsychotic Agents; Clozapine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Piperidines; Recurrence; Risperidone; Schizophrenia; Schizophrenia, Paranoid | 1995 |
Clozapine in the management of schizophrenia. Risperidone is less toxic but equally effective.
Topics: Antipsychotic Agents; Clozapine; Drug Costs; Humans; Isoxazoles; Piperidines; Risperidone; Schizophrenia | 1993 |
Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients.
Topics: Antipsychotic Agents; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Isoxazoles; Piperidines; Remoxipride; Risperidone; Schizophrenia | 1993 |
Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry.
Topics: Animals; Antipsychotic Agents; Chromatography, Liquid; Humans; Isoxazoles; Mass Spectrometry; Paliperidone Palmitate; Pyrimidines; Rats; Risperidone; Schizophrenia; Sensitivity and Specificity | 2000 |
Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Female; Humans; Isoxazoles; Male; Middle Aged; Paliperidone Palmitate; Pyrimidines; Risperidone; Schizophrenia | 2001 |
Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Isoxazoles; Male; Middle Aged; Pilot Projects; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia | 1991 |